# EDGAR Filing Document

**Accession Number:** 0001615219
**File Stem:** 0001193125-26-256541
**Filing Date:** 2026-6
**Character Count:** 156107
**Document Hash:** 6bd89c5ed74f7c3f460c3f2eb7f9c12f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-256541.hdr.sgml**: 20260604

**ACCESSION NUMBER**: 0001193125-26-256541

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20260604

**FILED AS OF DATE**: 20260604

**DATE AS OF CHANGE**: 20260604

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Decoy Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001615219
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 465087339
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36812
- **FILM NUMBER:** 261063282

**BUSINESS ADDRESS:**
- **STREET 1:** 2450 HOLCOMBE BLVD
- **STREET 2:** SUITE J-608
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77021
- **BUSINESS PHONE:** 346-772-0346

**MAIL ADDRESS:**
- **STREET 1:** 2450 HOLCOMBE BLVD
- **STREET 2:** SUITE J-608
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Salarius Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20190723

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Flex Pharma, Inc.
- **DATE OF NAME CHANGE:** 20140730

?xml version='1.0' encoding='ASCII'? DEF 14A

[**<u>**Table of Contents**</u>**](#toc_page)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

---

| |
|:---|
| Decoy Therapeutics Inc. |
| **(Name of Registrant as Specified in its Charter)** |

---

Not Applicable.

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**DECOY THERAPEUTICS INC.**

**2450 Holcombe Blvd.**

**Suite X**

**Houston, TX 77021**

**713-913-5608**

**NOTICE OF ANNUAL MEETING OF STOCKHOLDERS**

**To Be Held July 14, 2026**

To Our Stockholders:

NOTICE IS HEREBY GIVEN that Decoy Therapeutics Inc. will hold its 2026 Annual Meeting of Stockholders (the "Annual Meeting") at 10:00 AM, CST, on Tuesday, July 14, 2026. This year's Annual Meeting will be held solely by means of live audio webcast online at https://web.viewproxy.com/dcoy/2026. For instructions on how to attend and vote your shares at the Annual Meeting, see the information in the accompanying Proxy Statement in the section titled "Information Concerning Voting and Solicitation - Questions and Answer About These Proxy Material and Voting." The items of business for the meeting are to consider and vote on the following matters described in the accompanying proxy statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.To elect three Class II directors to our Board of Directors (our "Board of Directors"), each to serve until our 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified ("Proposal 1").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in the attached proxy statement ("Proposal 2").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 ("Proposal 3").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting.

The Board of Directors recommends that stockholders vote "**FOR**" each of the director nominees listed in Proposal 1 and "**FOR**" Proposals 2 and 3.

Only stockholders of record at the close of business on May 22, 2026 are entitled to notice of, and to vote while attending the Annual Meeting on the Internet.

We are using the "Notice and Access" method of providing proxy materials to you via the Internet. We are mailing to you a Notice of Internet Availability of Proxy Materials instead of paper copies of this Notice of 2026 Annual Meeting of Stockholders and Proxy Statement (this Notice and Proxy Statement) and our Annual Report on Form 10-K for the year ended December 31, 2025 (Annual Report), as amended. Notice and Access provides a convenient way for you to access our proxy materials. The Notice of Internet Availability of Proxy Materials includes instructions on how to access this Notice and Proxy Statement and our Annual Report and how to vote your shares. The Notice of Internet Availability of Proxy Materials also contains instructions on how to receive a paper copy of the proxy materials and our Annual Report, if you prefer.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The accompanying proxy statement includes further details with respect to the proposals to be considered at the Annual Meeting. This Notice and the accompanying proxy statement contain important information and should be read in their entirety. If you are in doubt as to how you should vote at the Annual Meeting, you should seek advice from your legal counsel, accountant or other professional adviser prior to voting.

By the Order of the Board of Directors

/s/ Frederick E. Pierce

Frederick E. Pierce

Chief Executive Officer and Director

Houston, Texas

June 4, 2026

**Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on July 14, 2026:**

**Copies of our Proxy Materials, consisting of the Notice of Annual Meeting of Stockholders, the Proxy Statement and Accompanying Form of Proxy Card, and our 2025 Annual Report on Form 10-K, as amended, are available at: https://web.viewproxy.com/dcoy/2026** 

------

[**<u>**Table of Contents**</u>**](#toc_page)

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | PAGE |
| [INFORMATION CONCERNING VOTING AND SOLICITATION](#information_concerning_voting) | 1 |
| [QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING](#questions_and_answers) | 1 |
| [DIRECTORS AND EXECUTIVE OFFICERS](#directors_and_executive_officers) | 8 |
| [CORPORATE GOVERNANCE](#corporate_governance) | 13 |
| [EXECUTIVE COMPENSATION](#executive_compensation) | 20 |
| [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#security_ownership_of_certain) | 33 |
| [CERTAIN RELATED-PERSON TRANSACTIONS](#certain_related_person) | 35 |
| [PROPOSAL 1: ELECTION OF DIRECTORS](#proposal_1) | 39 |
| [PROPOSAL 2: NON-BINDING ADVISORY VOTE ON EXECUTIVE COMPENSATION](#proposal_2) | 40 |
| [PROPOSAL 3: RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM](#proposal_3) | 41 |
| [OTHER MATTERS](#other_matters) | 43 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**DECOY THERAPEUTICS INC.**

**PROXY STATEMENT**

**INFORMATION CONCERNING VOTING AND SOLICITATION**

This proxy statement is being furnished to you in connection with the solicitation by the board of directors (the "Board of Directors") of Decoy Therapeutics Inc. ("we," "us," "our," "Decoy" and the "Company"), a Delaware corporation, of your proxy to vote at our 2026 Annual Meeting of Stockholders and any adjournments or postponements thereof (the "Annual Meeting"). Our Annual Meeting will be held at 10:00 AM, CST, on Tuesday, July 14, 2026 via live webcast. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting https://web.viewproxy.com/dcoy/2026 and entering your control number that appears on your proxy card, on your proxy card or on the instructions that accompanied your proxy materials. If you lose your control number, you may join the Annual Meeting as a "Guest" but you will not be able to vote, ask questions or access the list of stockholders as of the close of business on May 22, 2026 (the "Record Date").

As used in this Proxy Statement, references to "we," "us," "our," "Decoy" and the "Company" refer to Decoy Therapeutics Inc. and our consolidated subsidiaries. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this Proxy Statement and references to our website address in this Proxy Statement are inactive textual references only.

**QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING**

**Q: Why am I receiving these materials?** 

A: Our Board of Directors is soliciting your proxy to vote at our Annual Meeting, including at any adjournments or postponements of the meeting. You are invited to attend the Annual Meeting via the webcast to vote on the proposals described in the proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may follow the instructions below to submit your proxy by telephone or through the Internet.

We intend to mail the Notice of Internet Availability of Proxy Materials (the "Notice") on or about June 4, 2026 to all stockholders of record entitled to vote at the Annual Meeting.

**Q: Why did I receive a notice regarding the availability of proxy materials on the Internet?** 

A: Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the Internet. Accordingly, we have sent you a Notice because the Board of Directors is soliciting your vote at the Annual Meeting, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice and may request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the Internet or to request a printed copy may be found in the Notice.

**Q: Will I receive any other proxy materials by mail?**

A: We may send you a proxy card, along with a second Notice, on or after June 4, 2026. In addition, if you wish, we will send you paper copies of our proxy materials, including a proxy card. Instructions on how to request paper copies of the proxy materials can be found in the Notice.

**Q: How can I attend the Annual Meeting?** 

A: The Annual Meeting will be a virtual meeting of stockholders, which will be conducted exclusively by live

audio webcast. Participants will receive an Internet link to where the audio webcast will be held once they register for the Annual Meeting. You are entitled to participate in the Annual Meeting only if you were a stockholder of record of

------

[**<u>**Table of Contents**</u>**](#toc_page)

the Company as of the close of business on May 22, 2026 (the "Record Date"), or if you hold a valid proxy for the Annual Meeting. No physical meeting will be held. The online meeting will begin promptly at 10:00 a.m., Central Time, on July 14, 2026. You may attend the Annual Meeting, vote, and submit a question during the Annual Meeting by webcast by first registering at https://web.viewproxy.com/DCOY/2026 by 11:59 PM CT on July 12, 2026. If you hold your shares in an account at a brokerage firm, bank, dealer or other similar organization, you will need to obtain a "legal proxy" from that entity and submit it when you register. On the day of the Annual Meeting, if you have properly registered, you may enter the meeting by clicking on the link provided via email in your registration confirmations. We encourage you to access the meeting prior to the start time leaving ample time for the check in. To vote at the meeting, (a) if you hold your shares through a broker, bank or other nominee, you will need the control number you receive by email after registering, and (b) if you hold your shares in an account with our transfer agent, you will need the control number that is shown on your Notice of Internet Availability of Proxy Materials or on your proxy card if you elected to receive proxy materials by mail.

**Q: Who can vote at the Annual Meeting?** 

A: Only stockholders of record at the close of business on the Record Date, May 22, 2026, will be entitled to vote at the Annual Meeting. On the Record Date, there were 531,968 shares of common stock outstanding and entitled to vote.

*Stockholder of Record: Shares Registered in Your Name* 

If on the close of business on the Record Date, your shares were registered directly in your name with our transfer agent, Equiniti Trust Company, LLC, then you are a stockholder of record. As a stockholder of record, you may vote online during the Annual Meeting, via the Internet, by mail, or by telephone as described below. Giving a proxy will not affect your right to vote during the Annual Meeting. Whether or not you plan to attend the meeting, we urge you to vote promptly to ensure your vote is counted.

*Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Nominee*

If on the close of business on the Record Date, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in "street name" and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct that organization regarding how to vote the shares in your account. Stockholders holding shares through a broker, bank or other nominee should follow the instructions in the materials received from that organization.

**Q: What am I voting on?** 

A: There are three matters scheduled for a vote:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.To elect three Class II directors to our Board of Directors, each to serve until our 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in this proxy statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.To ratify the appointment, by the Audit Committee of the Board of Directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.

**Q: What are the Board of Directors' recommendations?** 

A: Our Board of Directors recommends that you vote:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**"FOR" ELECTION OF EACH OF THE NOMINEES FOR CLASS II DIRECTOR;**

------

[**<u>**Table of Contents**</u>**](#toc_page)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**"FOR" THE APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION PAID BY US TO OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT; AND**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**"FOR" RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.**

**Q: What if another matter is properly brought before the meeting?** 

A: The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the proxy holder to vote on those matters in accordance with their best judgment.

**Q: How do I vote?** 

*Stockholder of Record: Shares Registered in Your Name* 

If you are a stockholder of record, you may vote during the Annual Meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote at that time even if you have already voted by proxy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Voting via the Internet.* To vote through the Internet, go to www.AALvote.com/DCOY. Your vote must be received by 11:59 PM Eastern Time on July 13, 2026. We encourage you to vote via the Internet.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Voting by mail. To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered to you and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Voting by telephone. To vote over the telephone, dial toll-free 1-866-804-9616, using a touch-tone telephone and follow the recorded instructions. You will be asked to provide the control number from your Notice or proxy card. Your vote must be received by 11:59 PM Eastern Time on July 13, 2026 to be counted.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Voting at the Annual Meeting. To vote at the Annual Meeting, you must join live online using the unique join link provided after registration. The webcast will start at 10:00 a.m., Central Time, with log-in beginning at 9:45 a.m., Central Time. You may vote and submit questions while attending the meeting online. You will need the control number included on your Notice or your proxy card (if you received a printed copy of the proxy materials) to vote during the meeting.*

------

[**<u>**Table of Contents**</u>**](#toc_page)

*Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Nominee*

If you are a beneficial owner of shares registered in the name of your broker, bank or other nominee, you should have received a Notice containing voting instructions from that organization rather than from the Company. Simply follow the voting instructions in the Notice to ensure that your vote is counted. To vote at the Annual Meeting, you must obtain a valid proxy from your broker, bank or other nominee. Follow the instructions set forth on the Notice or from your broker, bank or other nominee or contact that organization to request a voting instruction form.

**We provide telephone and Internet proxy voting to allow you to vote your shares telephonically or online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your telephone or Internet access, such as usage charges from Internet access providers and telephone companies.** 

**Q: How many votes do I have?** 

A: On each matter to be voted upon, you have one vote for each share of common stock you own as of the close of business on the Record Date, which is May 22, 2026.

**Q: What happens if I do not vote?** 

*Stockholder of Record: Shares Registered in Your Name* 

If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the Internet, or at the Annual Meeting, your shares will not be voted.

*Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Nominee*

If you are a beneficial owner of shares held in "street name" and do not instruct your broker, bank, or other nominee how to vote your shares, the question of whether that organization will still be able to vote your shares depends on whether the particular proposal is deemed to be "routine" under the rules of the New York Stock Exchange (also applicable to companies listed on the Nasdaq Capital Market ("Nasdaq")). Brokers, banks and other nominees can use their discretion to vote "uninstructed" shares only with respect to matters that are considered to be "routine." They may not vote your shares with respect to matters that are considered "non-routine" and for these matters your shares will be left unvoted. "Non-routine" matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation), approval of equity incentive plans, and certain corporate governance proposals, even if management-supported. Proposal 3 (ratifying the appointment of our independent registered public accounting firm) is considered a routine matter under applicable NYSE rules. Proposal 1 (election of directors) and Proposal 2 (advisory vote on the approval of named executive officer compensation) are each considered a "non-routine" item for which brokers and nominees do not have discretionary voting power. If your broker, bank or other nominee returns a proxy card but does not vote your shares, this results in a "broker non-vote." Broker non-votes will be counted as present for the purpose of determining a quorum. However, as brokers, banks or other nominees do not have discretionary authority to vote on Proposals 1 and 2, broker non-votes will not be counted for the purpose of determining the number of shares entitled to vote on such proposals. Accordingly, your broker, bank or other nominee may not vote your shares on Proposals 1 or 2 without your instructions but may vote your shares on Proposal 3. If you are a beneficial owner of shares held in "street name" you must provide voting instructions to your broker, bank or other nominee by the deadline provided in the materials you receive from such organization in order to ensure your shares are voted in the way you would prefer.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Q: What if I return a proxy card or otherwise vote but do not make specific choices?** 

A: If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, "**FOR**" the election of each of the nominees for director, "**FOR**" the approval, on a non-binding advisory basis, of the named executive officer compensation, and "**FOR**" the ratification of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.

**Q: Who am I being asked to appoint as proxy holders and what does it mean?** 

A: Our Board of Directors asks you to appoint our Chief Executive Officer, Frederick E. Pierce, and our Chief Financial Officer, Mark J. Rosenblum, as your proxy holders to vote your shares at the Annual Meeting. You make this appointment when you vote.

If appointed by you, the proxy holders will vote your shares as you direct on the matters described in this proxy statement. In the absence of your direction, they will vote your shares as recommended by our Board of Directors.

Unless you otherwise indicate when you vote, you also authorize your proxy holders to vote your shares on any matters not known by our Board of Directors at the time this proxy statement was printed and which, under our amended and restated bylaws (the "Bylaws"), may be properly presented for action at the Annual Meeting.

**Q: Who is paying for this proxy solicitation?** 

A: We will pay the entire cost of the solicitation of proxies for the Annual Meeting. This includes preparation, assembly, printing, and mailing of the Notice, this proxy statement and any other information we send to stockholders. In addition, we may supplement our efforts to solicit your proxy in the following ways:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•we may contact you using the telephone or electronic communication;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our directors, officers or other regular employees may contact you personally; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•third parties we may hire as agents for the sole purpose of contacting you regarding your proxy, may contact you.

**Q: What does it mean if I receive more than one Notice?**

A: If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on each of the Notices to ensure that all of your shares are voted.

**Q: I share an address with another stockholder, and we received only one paper copy of the proxy materials. How may I obtain an additional copy of the proxy materials?**

A: We have adopted a procedure called "householding," which the SEC has approved. Under this procedure, we deliver a single copy of the Notice and, if applicable, our proxy materials to multiple stockholders who share the same address unless we have received contrary instructions from one or more of such stockholders. This procedure reduces our printing costs, mailing costs, and fees. Stockholders who participate in householding will continue to be able to access and receive separate proxy cards. Upon written or oral request, we will promptly deliver a separate copy of the Notice and, if applicable, our proxy materials to any stockholder at a shared address to which we delivered a single copy of any of these materials. To receive a separate copy, or, if a stockholder is receiving multiple copies, to request that we only send a single copy of the Notice and, if applicable, our proxy materials, such stockholder may contact us at the following address:

Decoy Therapeutics Inc.

Attention: Investor Relations

2450 Holcombe Blvd

Suite X

------

[**<u>**Table of Contents**</u>**](#toc_page)

Houston, TX 77021

713-913-5608

Street name stockholders may contact their broker, bank, or other nominee to request information about householding.

**Q: Can I change or revoke my vote after submitting my proxy?** 

A: Stockholder of Record: Shares Registered in Your Name Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•You may submit a properly completed proxy card with a later date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•You may grant a subsequent proxy by telephone or through the Internet.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•You may send a timely written notice that you are revoking your proxy to our Secretary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•You may attend the Annual Meeting via the live webcast and vote. Attendance at the Annual Meeting will not cause your previously granted proxy to be revoked unless you specifically so request.

We count your most current proxy card or telephone or Internet proxy.

*Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Nominee* 

A: Stockholders holding shares through a broker, bank or other nominee should follow the instructions for revocation received from that organization.

**Q: How are Abstentions, Withheld and Broker Non-Votes counted?** 

A: For Proposal 1, the election of directors, you may vote "**FOR**" each of the Class II nominees, vote "**AGAINST**" any or all of the Class II nominees or "**ABSTAIN**" with respect to any or all of the Class II nominees. An abstention has the same effect as a vote "**AGAINST**" a director nominee in Proposal 1. Broker non-votes will have no effect.

For Proposal 2, the approval, on a non-binding advisory basis, of the compensation of our named executive officers, you may vote "**FOR**," vote "**AGAINST**" or "**ABSTAIN**." An abstention has the same effect as a vote "**AGAINST**" Proposal 2. Broker non-votes will have no effect.

For Proposal 3, the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026, you may vote "**FOR**", vote "**AGAINST**" or "**ABSTAIN**". An abstention has the same effect as a vote "**AGAINST**" Proposal 3. Broker non-votes will have no effect.

**Q: How many votes are needed to approve each proposal?**

A: For Proposal 1, the election of the directors, a nominee receiving the affirmative vote of a majority of the voting power of the capital stock entitled to vote and present in person or represented by proxy at the Annual Meeting will be elected. Further, if the majority of the votes cast for a director are marked "AGAINST" or "ABSTAIN" then notwithstanding the valid election of such director, the Bylaws stipulate that such director will voluntarily tender his or her irrevocable resignation for consideration by our Nominating and Corporate Governance Committee. Our Board of Directors will determine whether to accept the resignation of such director, taking into account the recommendation of the Nominating and Corporate Governance Committee.

For Proposal 2, the approval, on a non-binding advisory basis, of the compensation of our named executive officers, requires the affirmative vote of a majority of the voting power of the capital stock entitled to vote and present in person or represented by proxy at the Annual Meeting.

------

[**<u>**Table of Contents**</u>**](#toc_page)

For Proposal 3, the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026, requires the affirmative vote of a majority of the voting power of the capital stock entitled to vote and present in person or represented by proxy at the Annual Meeting.

**Q: What is the quorum requirement?** 

A: A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least 34% of the outstanding shares entitled to vote are present in person at the meeting or represented by proxy. As of the close of business on the Record Date, there were 531,968 shares outstanding and entitled to vote.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank, or other nominee) or if you vote by telephone, over the Internet or at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum either any officer entitled to preside at such meeting or the holders of a majority of the shares present in person at the meeting or represented by proxy and entitled to vote may adjourn the meeting from time to time until a quorum shall be present or represented.

**Q: How can I find out the results of the voting at the Annual Meeting?** 

A: Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.

**Important**

**Please promptly vote by telephone or the Internet, or by following the instructions provided by your bank, broker or nominee, so that your shares can be represented at the Annual Meeting. This will not limit your rights to attend or vote during the Annual Meeting. Please note, however, that if you wish to vote at the Annual Meeting, you must register in advance, following the instructions above.**

------

[**<u>**Table of Contents**</u>**](#toc_page)

**DIRECTORS AND EXECUTIVE OFFICERS**

**Directors** 

Our Board of Directors consists of seven (7) directors which are divided into three classes: Class I, Class II, and Class III. Each class has a three-year term:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Our Class I directors are Arnold C. Hanish and William K. McVicar and their terms will expire at the annual meeting of stockholders to be held in 2028.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Our Class II directors are David J. Arthur, Jonathan Lieber, and Frederick E. Pierce and their terms will expire at the Annual Meeting. Mr. Arthur is not standing for re-election and our Board of Directors has nominated Patricia Gauthier to fill the vacancy left by Mr. Arthur.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Our Class III directors are Tess Burleson and Paul Lammers and their terms will expire at the annual meeting of stockholders to be held in 2027.

Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of our Board of Directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of the Company. Our directors may be removed for cause by the affirmative vote of the holders of at least two-thirds of our voting stock of the capital stock issued and outstanding then entitled to vote at an election of directors.

The following table sets forth the name, age and committee appointments of each of the Company's current directors and nominees as of April 30, 2026:

---

| | | |
|:---|:---|:---|
| <br>**Name** | **Age** | **Position** |
| Frederick E. Pierce<sup>(1)(5)</sup> | 64 | Chief Executive Officer and Director |
| William K. McVicar | 68 | Chair |
| David J. Arthur | 63 | Director |
| Tess Burleson<sup>(2)(3)(4)</sup> | 59 | Director |
| Arnold C. Hanish<sup>(2)(4)</sup> | 78 | Director |
| Paul Lammers<sup>(4)</sup> | 68 | Director |
| Jonathan Lieber<sup>(2)(3)(5)</sup> | 56 | Director |
| Patricia Gauthier<sup>(5)</sup> | 49 | Nominee for Director |

---

(2)Member of the Audit Committee.

(3)Member of the Nominating and Corporate Governance Committee.

(4)Member of the Compensation Committee.

(5)Nominee for election at the Annual Meeting.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The names of the nominees and certain biographical information about each current director, including a description of his or her business experience, qualifications, education and skills that led our Board of Directors to conclude that such individual should serve as a member of our Board of Directors, are set forth below:

***Nominees for Election at the Annual Meeting for a Three-Year Term***

*Patricia Gauthier*

Ms. Gauthier has served as Senior Vice President, Regional Head for Australia, Canada and the United Kingdom at Moderna since 2025, where she leads end-to-end strategy and operations across biomanufacturing, national health security partnerships, R&D collaborations and commercialization of in-market and pipeline products. She oversees significant regional investment, regional P&L, and approximately 500 employees across direct and matrixed teams.

Previously, Ms. Gauthier held several senior roles at Moderna, including General Manager of Moderna Canada, where she built the Canadian affiliate from inception, supported delivery of more than 50 million COVID-19 vaccine doses, and helped secure a landmark biomanufacturing partnership with the Government of Canada. She also led the creation of Moderna's global rare disease business and defining its global strategy, operating model and go-to-market approach. Before Moderna, Ms. Gauthier held multiple senior leadership roles at GSK across vaccines, specialty care, general medicines, market access and government affairs. Earlier in her career, she practiced law at McCarthy Tétrault LLP.

Ms. Gauthier serves on the boards of AdMare BioInnovations (Canadian private company). She holds an MBA from HEC Montréal and an LL.B. from the Université de Sherbrooke in Canada, with executive education from Harvard Business School (negotiation) and IMD (leadership).

The Board of Directors believes that Ms. Gauthier is qualified to serve on the Board of Directors due to her extensive experience in the biotechnology industry and her experience as a senior executive of a leading public company in the life sciences space.

*Jonathan Lieber*

Mr. Lieber has served as a member of the Board of Directors since June 2020. Since February 2023, he has served as Chief Financial Officer and Treasurer of Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. From September 2021 until its sale in November 2022, he served as Chief Financial Officer of Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases. From December 2018 through September 2021, Mr. Lieber served as a Managing Director of Danforth Advisors LLC, a firm that provides strategic CFO advisory and outsourced accounting services to healthcare companies. In that capacity, he served as interim CFO for several private and public healthcare companies. From July 2015 through September 2019, Mr. Lieber was Chief Financial Officer of Histogenics Corporation (Nasdaq: HSGX) a cell therapy company developing products for the orthopedics market. Mr. Lieber received an M.B.A. in finance from the Stern School of Business of New York University and a B.S. in business administration from Boston University.

The Board of Directors believes that Mr. Lieber is qualified to serve on the Board of Directors due to his experience in the healthcare industry, which will enable him to contribute important strategic insights to the Company.

*Frederick E. Pierce*

Mr. Pierce has served as a member of the Board of Directors and as the Company's Chief Executive Officer since November 12, 2025. Mr. Pierce was a co-founder of Legacy Decoy and served as Legacy Decoy's Chief Executive Officer and a member of its board of directors from 2020 until the closing of the Merger. From September 2022 until November 2024, Mr. Pierce served as an executive officer of Innovation1 Biotech, Inc., a drug discovery company. Mr. Pierce is also an advisor to the Canadian Consulate of Boston/Cambridge's Healthcare and Technology

------

[**<u>**Table of Contents**</u>**](#toc_page)

Accelerator and a board member of the Canadian Entrepreneurs of New England, where he is Chairman of the Life Sciences Leadership Council. From 2017 through 2020, Mr. Pierce served as a Senior Advisor for Bionest Partners, a life sciences consulting company. Mr. Pierce is a biotech entrepreneur with over 20 years of increasing senior leadership and operating experience building successful biotechnology companies.

The Board of Directors believes that Mr. Pierce is qualified to serve on the Board of Directors based on his service as the Company's Chief Executive Officer, his role as co-founder and Chief Executive Officer of Legacy Decoy, and his extensive experience building and leading biotechnology companies.

***Directors Continuing in Office Until the 2027 Annual Meeting***

*Tess Burleson*

Ms. Burleson has served as a member of the Board of Directors since July 2019. Ms. Burleson is a Certified Public Accountant and has served as the chief operating officer of TGen, a Medical R&D organization, since 2007, and has served as the president of TGen Health Ventures, LLC, a venture capital company, since 2009. She also serves as an advisor to bankers and investors in the life sciences industry. Prior to joining TGen, Ms. Burleson served as the chief financial officer at Lovelace Health System enterprises from 1997 to 2007, president at Lovelace Scientific Resources from 1993 to 1997, and as a senior associate at KPMG from 1990 to 1993. Ms. Burleson earned an advanced finance certification from The Wharton School at the University of Pennsylvania, a B.B.A. from Robert O. Anderson School of Business at the University of New Mexico and her M.B.A. from the Anderson Graduate School of Management at the University of New Mexico.

The Board of Directors believes that Ms. Burleson is qualified to serve on the Board of Directors as a result of her extensive operational experience in the biotechnology industry and experience in financial and accounting matters.

*Paul Lammers, MD, MSc* 

Dr. Lammers has served as a member of the Board of Directors since July 2019 and previously served as the Company's lead independent director. In February 2024, Dr. Lammers retired as CEO of Triumvira Immunologics, a privately held engineered T cell therapy company and for which he raised over $125 million from leading venture firms, where he served starting in 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing (Nasdaq: MRNA) in 2015. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono. During his early industry tenure, Dr. Lammers also held various executive and senior management positions in clinical development, medical and regulatory affairs at different pharmaceutical companies, as well as at small public and privately held biotechnology companies. Dr. Lammers serves as Director for private oncology biotechnology company Immunomet Therapeutics, and private oncology biotechnology company Diakonos Oncology. Dr. Lammers obtained both his Master of Science in Biology and his Medical Degree from Radboud University, Nijmegen, The Netherlands.

The Board of Directors believes that Dr. Lammers is qualified to serve on the Board of Directors as a result of his extensive experience in the pharmaceutical industry and deep understanding of oncology drugs.

***Directors Continuing in Office Until the 2028 Annual Meeting***

*Arnold Hanish*

Mr. Hanish has served as a member of the Board of Directors since July 2019. Mr. Hanish served in various management roles at Eli Lilly and Company, a pharmaceutical company, including Vice President and Chief Accounting Officer. Prior to Eli Lilly and Company, Mr. Hanish held numerous positions at Arthur Young & Company (currently Ernst & Young) from 1970 to 1984, including being the Director of Tax in the Indianapolis office from 1979 to 1984. Mr. Hanish served as a member of the Deloitte and Touche, LLP, a professional services company, Audit Quality Review Council from 2013 to 2023. In addition, since September 2012, Mr. Hanish has served on the board of directors of Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company, and chairs

------

[**<u>**Table of Contents**</u>**](#toc_page)

its Audit Committee. From 2007 to 2010, Mr. Hanish served as the Chairperson of the Financial Executives International Committee on Corporate Reporting and was on their SEC and Public Company Accounting Oversight Board ("PCAOB") subcommittees. In 2016, Mr. Hanish was inducted into the Financial Executives International Hall of Fame. From 2004 to 2008 and again in 2011 and 2012, Mr. Hanish was a member of the Standing Advisory Group of the PCAOB, a nonprofit audit oversight organization. Since 2010, Mr. Hanish has served on the Dean of the College of Business's Business Advisory Council and recently received the Distinguished Service Award from the college of business at the University of Cincinnati. Mr. Hanish earned a B.B.A. in Accounting from the University of Cincinnati and is a licensed CPA in Indiana and Ohio.

The Board of Directors believes that Mr. Hanish is qualified to serve on the Board of Directors as a result of his experience in the pharmaceutical industry, as well as deep experience in accounting and public company financial matters.

*William McVicar, Ph.D.*

Dr. McVicar has served as a member of the Board of Directors since the completion of the reverse acquisition in July 2019. Prior to completion of the acquisition, Dr. McVicar served as a member of the board of directors of Flex Pharma, Inc. ("Flex Pharma") since August 2017, and served as its chief executive officer from July 2017 to July 2019. Dr. McVicar joined Flex Pharma in April 2017 as President of Research & Development. Prior to joining Flex Pharma, Dr. McVicar also serves as president and CEO of Neuromity Therapeutics, LLC since November 2021 and serves as Chief Operating Officer (acting) at Satellos Biosciences, Inc. since July 2020. Additionally, Dr. McVicar served as Executive Vice President of pharmaceutical development, chief scientific officer and president during his tenure at Inotek Pharmaceuticals Corporation from September 2007 to April 2017. Dr. McVicar also held various positions at Sepracor, Inc., Novartis AG and RPR Gencell, the Gene and Cell Therapy Division of Rhone Poulenc Rorer. Dr. McVicar earned his B.S. in Chemistry from the State University of New York College at Oneonta and his Ph.D. in Chemistry from the University of Vermont.

The Board of Directors believes that Dr. McVicar is qualified to sit on the Board of Directors due to his over 30 years of biologic and drug development experience and his experience as a senior executive.

**Executive Officers**

The following table shows information about our executive officers as of May 22, 2026:

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| Frederick E. Pierce | 64 | Chief Executive Officer and Director |
| Mark J. Rosenblum | 72 | Executive Vice President of Finance and Chief Financial Officer |
| Barbara Hibner, Ph.D. | 65 | Chief Scientific Officer |
| Peter Marschel | 52 | Chief Business Officer |

---

The following presents biographical information for each of the Company's executive officers in the table above, other than for Mr. Pierce, whose information is presented above under "Class II Directors."

*Mark J. Rosenblum*

Mr. Rosenblum has served as the Company's Executive Vice President of Finance and Chief Financial Officer since September 2019. In addition, Mr. Rosenblum served as the Company's principal executive officer as Acting Chief Executive Officer from August 17, 2025 until November 12, 2025, the effective date on which Mr. Pierce was appointed as the Company's Chief Executive Officer. Prior to September 2019, Mr. Rosenblum served as a financial consultant to the Company since February 2019. Prior to joining the Company, Mr. Rosenblum served as chairman, chief executive officer and a director of ActiveCare, Inc. (Nasdaq: ACAR), a healthcare company, from December 2017 to March 2019, which was sold to Biotelemetry, Inc. (now Royal Philips (NYSE: PHG)). Mr. Rosenblum worked as a financial consultant for various companies from 2014 to 2017. Prior to that, Mr. Rosenblum served as the chief financial officer of Advaxis, Inc. (Nasdaq: ADXS), a biotechnology company, from January 2010 to April 2014. From

------

[**<u>**Table of Contents**</u>**](#toc_page)

1985 through 2003, Mr. Rosenblum was employed by Wellman, Inc., a global public chemical manufacturer, which was subsequently acquired by DAK Americas, serving in various capacities including chief accounting officer. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina. Mr. Rosenblum began his career in 1977 with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years, and is currently a member of the American Institute of Certified Public Accountants.

*Barbara Hibner, Ph.D.*

Dr. Hibner has served as the Company's Chief Scientific Officer since November 12, 2025. Dr. Hibner was a co-founder of Legacy Decoy and served as its Chief Scientific Officer, director and Board Chair from 2020 until the closing of the Merger. From January 2017 to April 2020, Dr. Hibner was co-founder and Chief Executive Officer of PercepTx, a targeted cancer immunotherapy company focused on using computational modeling and quantitative pharmacology to discover and develop novel antibody drug conjugates. Prior to that, she served in a range of scientific and managerial positions in discovery, pharmacology and research quality roles at Bayer Pharmaceuticals, Chiron, Millennium and Takeda Pharmaceuticals. Dr. Hibner's work has contributed to the approval of two small molecule drugs, sorafenib and ixazomib.

*Peter Marschel*

Mr. Marschel has served as the Company's Chief Business Officer since November 12, 2025. Mr. Marschel was a co-founder of Legacy Decoy and served as its Chief Business Officer and director from 2020 until the closing of the Merger. Until April 2020, Mr. Marschel was co-founder and Chief Financial Officer of PercepTx, a targeted cancer immunotherapy accelerator focused on using computational modeling and quantitative pharmacology to rapidly increase the value of preclinical monoclonal antibody-based therapeutic assets. Prior to that, he served in a range of business development, analytics, and commercial roles at Merck, Vertex Pharmaceuticals, and Takeda Pharmaceuticals, including leading market analytics for the cystic fibrosis franchise at Vertex Pharmaceuticals.

**Family Relationships**

There are no family relationships among any of our directors or executive officers.

**Arrangements between Officers and Directors**

Pursuant to the Merger Agreement, Mr. Pierce was appointed to serve as a Class II director of the Company and as the Company's Chief Executive Officer in connection with the closing of the Merger. To the Company's knowledge, there is no other arrangement or understanding between any of the Company's officers and any other person, including directors, pursuant to which the officer was selected to serve as an officer.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**CORPORATE GOVERNANCE**

**Board of Directors**

Our business and affairs are organized under the direction of the Board of Directors, which currently consists of seven members. Dr. McVicar currently serves as the Chair of our Board of Directors. The primary responsibilities of our Board of Directors are to provide oversight, strategic guidance, counseling, and direction to our management. Our Board of Directors meets on a regular basis and additionally as required.

***Director Independence*** 

The Nasdaq Listing Rules generally require that a majority of the members of a listed company's board of directors must qualify as "independent" as affirmatively determined by its board of directors. The Board of Directors consults with the Company's counsel to ensure that the Board of Directors' determinations are consistent with relevant securities and other laws and regulations regarding the definition of "independent," including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

The Board of Directors has undertaken a review of its composition, the composition of its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, the Board of Directors has determined that each of Dr. McVicar, Ms. Burleson, Mr. Hanish, Dr. Lammers, and Mr. Lieber, is "independent" as that term is defined under the applicable rules and regulations of the SEC and the listing requirements of Nasdaq, , and that Ms. Gauthier, assuming election, will qualify as independent. Dr. McCreedy, who resigned from the Board of Directors on November 12, 2025, was also determined by the Board of Directors to be "independent" during his tenure in 2025.

The Board of Directors has determined that Mr. Pierce, the Company's Chief Executive Officer, is not independent under the applicable rules and regulations of the SEC and Nasdaq Listing Rules. The Board of Directors has also determined that Mr. Arthur is not independent under such rules and regulations because Mr. Arthur served as the Company's Chief Executive Officer, including in his role as a part-time consultant pursuant to the Consulting Agreement, within the three-year look-back period set forth in Nasdaq Listing Rule 5605(a)(2). In making these determinations, the Board of Directors considered the current and prior relationships that each non-employee director has with the Company and all other facts and circumstances the Board of Directors deemed relevant in determining their independence, including the beneficial ownership of the Company's capital stock by each non-employee director.

***Board Leadership Structure***

Our Bylaws provide that if a chair of the Board of Directors is appointed, that person will preside at all meetings of the Board of Directors at which they are present. Currently, the position of chair of the Board of Directors is filled by Dr. McVicar.

The Board of Directors periodically reviews its leadership structure and developments in the area of corporate governance to ensure that this approach continues to strike the appropriate balance for the Company and our stockholders.

***Anti-Hedging Policy; Policy on Pledging***

We have an insider trading policy that sets forth guidelines and restrictions applicable to transactions involving our stock by our directors, officers and employees. Among other things, this policy prohibits our directors, officers and employees from engaging in purchases or sales of puts, calls, options or other derivative securities based on the Company's securities. These hedging transactions are prohibited because they would allow directors, officers and employees to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, their interests and the interests of the Company and its stockholders may be misaligned and may signal a message to the trading market that may not be in the best interests of the Company and its stockholders at the time it is conveyed. The insider trading policy also prohibits directors and officers from engaging in short sales of the Company's securities. Our Insider Trading Policy does not cover transactions of our securities by the Company itself.

------

[**<u>**Table of Contents**</u>**](#toc_page)

***Role of our Board of Directors in Risk Oversight***

One of the key functions of the Board of Directors is informed oversight of our risk management process. Our Board of Directors does not have a standing risk management committee, but rather administers this oversight function directly through our Board of Directors as a whole, as well as through various standing committees of our Board of Directors that address risks inherent in their respective areas of oversight. In particular, our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements. Our Compensation Committee also assesses and monitors whether our compensation plans, policies, and programs comply with applicable legal and regulatory requirements.

**Committees of the Board of Directors**

Our Board of Directors has established an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. Our Board of Directors has adopted a charter for each of these committees, each of which complies with the applicable requirements of current Nasdaq rules. We intend to comply with future requirements to the extent they are applicable to us. Copies of the charters for each committee are available on the investor relations portion of our website at www.decoytx.com.

***Audit Committee*** 

The Audit Committee currently consists of Ms. Burleson, Mr. Hanish, and Mr. Lieber. Mr. Hanish serves as the chair of our Audit Committee. The Board of Directors has determined that each of the members of the Audit Committee satisfies Nasdaq and SEC independence requirements. The Board of Directors has determined that Mr. Hanish qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq Listing Rules. In making this determination, the Board of Directors has considered Mr. Hanish's business background and previous experience. Both our independent registered public accounting firm and management periodically meet with the Audit Committee.

The functions of this committee include, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•selecting, on behalf of the Board of Directors, an independent public accounting firm to audit our financial statements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing our financial reporting processes and disclosure controls;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•discussing with the independent auditors their independence, and reviewing and discussing our audited financial statements with the independent auditors and management;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•recommending to the Board of Directors whether the audited financials should be included in our annual reports to be filed with the SEC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•overseeing management's identification, evaluation, and mitigation of major risks to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing and considering "related person transactions" under our Related Person Transaction Policy; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing any proposed waiver of our Code of Business Conduct and Ethics and Code of Ethics for Senior Financial Officers and making recommendations to the Board of Directors with respect to the disposition of any proposed waiver.

We believe that the composition and functioning of our Audit Committee complies with all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended (the "Sarbanes-Oxley Act") and all applicable SEC rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.

***Compensation Committee*** 

------

[**<u>**Table of Contents**</u>**](#toc_page)

Our Compensation Committee currently consists of Ms. Burleson, Mr. Hanish, and Dr. Lammers. Dr. Lammers serves as the chair of our Compensation Committee. The Board of Directors has determined that each of the members of the Compensation Committee is a non-employee director, as defined in Rule 16b-3 of the Exchange Act. Additionally, the Board has determined that each of the members of the Compensation Committee satisfies Nasdaq and SEC independence requirements.

The functions of this committee include, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing and approving the corporate objectives that pertain to the determination of executive compensation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing and approving the compensation and other terms of employment of our executive officers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing and approving performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•making recommendations to our Board of Directors regarding the adoption or amendment of equity and cash incentive plans and approving amendments to such plans to the extent authorized by our Board of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing and making recommendations to our Board of Directors regarding the type and amount of compensation to be paid or awarded to our non-employee board members;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•approving equity compensation plans and the grant of equity awards not subject to stockholder approval under applicable listing standards;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•overseeing the administration of our employee benefit plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing and assessing the independence of compensation consultants, legal counsel, and other advisors as required by Section 10C of the Exchange Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing and approving the terms of any employment agreements, severance arrangements, change in control protections, indemnification agreements, and any other material arrangements for our executive officers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing with management our disclosures under the caption "Compensation Discussion and Analysis" in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•monitoring our compliance with the requirements under the Sarbanes-Oxley Act relating to loans to directors and officers, and with all other applicable laws affecting employee compensation and benefit;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•preparing an annual report on executive compensation that the SEC requires in our annual proxy statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing and evaluating on an annual basis the performance of the Compensation Committee and recommending such changes as deemed necessary with our Board of Directors.

We believe that the composition and functioning of our Compensation Committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.

***Nominating and Corporate Governance Committee*** 

Our Nominating and Corporate Governance Committee consists of Ms. Burleson and Mr. Lieber. Ms. Burleson serves as the chair of our Nominating and Corporate Governance Committee. During fiscal year 2025 and until his resignation on November 12, 2025, Dr. McCreedy served as a member of the Nominating and Corporate Governance Committee. The Board of Directors has determined that each of the members of the Nominating and Corporate Governance Committee satisfies Nasdaq and SEC independence requirements. The functions of this committee include, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•identifying, reviewing, and making recommendations of candidates to serve on our Board of Directors;

------

[**<u>**Table of Contents**</u>**](#toc_page)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•evaluating the performance of our Board of Directors, committees of the Board of Directors, and individual directors and determining whether continued service on our Board of Directors is appropriate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•establishing procedures for nominations by stockholders of candidates for election to the Board of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•evaluating nominations by stockholders of candidates for election to the Board of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•overseeing the self-evaluation process of the Board of Directors and each of its committees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•evaluating the current size, composition, and organization of our Board of Directors and its committees and making recommendations to our Board of Directors for approvals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•developing a set of corporate governance policies and principles and recommending to our Board of Directors any changes to such policies and principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing issues and developments related to corporate governance and identifying and bringing to the attention of our Board of Directors current and emerging corporate governance trends; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reviewing periodically the Nominating and Corporate Governance Committee charter, structure, and membership requirements and recommending any proposed changes to our Board of Directors, including undertaking an annual review of its own performance.

We believe that the composition and functioning of our Nominating and Corporate Governance Committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.

**Board and Committee Meeting Attendance**

In 2025, our Board of Directors held 21 meetings. Each of our directors attended at least 75% of the aggregate number of meetings of our Board of Directors and meetings of any committee of which he or she was a member, which were held during the time in which he or she was a director or a committee member, as applicable. Our non-management directors meet in regularly scheduled sessions without the presence of management in executive sessions. Our Audit Committee held four meetings, our Compensation Committee and Nominating and Corporate Governance Committee did not hold any meeting in 2025. Directors are encouraged to attend our annual meeting of stockholders, either via webcast or telephonically.

**Code of Ethics**

The Board of Directors has adopted a Code of Business Conduct and Ethics (the "Code of Conduct") applicable to all of our employees, executive officers, and directors. The Code of Conduct is available on our website at www.decoytx.com. Information contained on or accessible through our website is not a part of this report, and the inclusion of our website address in this report is an inactive textual reference only. The Nominating and Corporate Governance Committee is responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers, and directors. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website.

We also implemented whistleblower procedures that establish formal protocols for receiving and handling complaints from employees. Any concerns regarding accounting or auditing matters reported under these procedures will be communicated promptly to our Audit Committee.

**Director Nominations**

Our Board of Directors nominates directors for election at each annual meeting of stockholders and elects new directors to fill vacancies when they arise. Our Nominating and Corporate Governance Committee has the responsibility to identify, evaluate, recruit, and recommend qualified candidates to our Board of Directors for nomination or election.

------

[**<u>**Table of Contents**</u>**](#toc_page)

*Director Criteria.* Our Nominating and Corporate Governance Committee has a policy regarding consideration of director candidates recommended by stockholders. Our Nominating and Corporate Governance Committee reviews suggestions for director candidates recommended by stockholders and considers such candidates for recommendation based upon an appropriate balance of knowledge, experience, and capability. In addition to considering an appropriate balance of knowledge, experience, and capability, our Board of Directors has as an objective that its membership be composed of experienced and dedicated individuals with diverse backgrounds, perspectives, skills, genders, and ethnicities. Our Nominating and Corporate Governance Committee selects director candidates based on the candidate possessing relevant market and technological expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment, diversity, potential for long-term contribution to the Company's business, and having the commitment and vision to rigorously represent the long-term interests of the Company's stockholders. Our Nominating and Corporate Governance Committee believes it is appropriate for a majority of the members of our Board of Directors to meet the definition of "independent director" under the Nasdaq rules. Our Nominating and Corporate Governance Committee also believes it appropriate for our Chief Executive Officer to participate as a member of our Board of Directors.

Prior to each annual meeting of stockholders, our Nominating and Corporate Governance Committee first identifies nominees by reviewing the current directors whose terms expire at the annual meeting of stockholders and who are willing to continue in service. These candidates are evaluated based on the criteria described above, including as demonstrated by the candidate's prior service as a director, and the needs of our Board of Directors, with respect to the particular talents and experience of its directors. If a director does not wish to continue in service, the Nominating and Corporate Governance Committee determines not to nominate the director, or a vacancy is created on our Board of Directors as a result of a resignation, an increase in the size of our Board of Directors or other event, the Nominating and Corporate Governance Committee will consider various candidates for Board membership, including those suggested by members of the Nominating and Corporate Governance Committee, by other members of our Board of Directors, by any executive search firm engaged by the Nominating and Corporate Governance Committee, and by stockholders. A stockholder who wishes to suggest a prospective nominee for our Board of Directors should notify our Secretary, any member of the Nominating and Corporate Governance Committee, or the persons referenced below in "Communications with our Board of Directors" in writing with any supporting material the stockholder considers appropriate.

*Stockholder Nominees.* In addition, our Bylaws contain provisions that address the process by which a stockholder may nominate an individual to stand for election to our Board of Directors at our annual meeting of stockholders. In order to nominate a candidate for director, a stockholder must give timely notice in writing to our Secretary and otherwise comply with the provisions of our Bylaws. To be timely, our Bylaws provide that we must have received the stockholder's notice not more than 120 days nor less than 90 days prior to the anniversary of the previous year's proxy statement provided in connection with the previous year's annual meeting of stockholders. Information required by our Bylaws to be in the notice include the name and contact information for the candidate and the person making the nomination and other information about the nominee that must be disclosed in proxy solicitations under Section 14 of the Exchange Act and the related rules and regulations under that section.

Stockholder nominations must be made in accordance with the procedures outlined in, and include the information required by, our Bylaws and must be addressed to: Secretary, Decoy Therapeutics Inc., 2450 Holcombe Blvd., Suite X, Houston, TX 77021. You can obtain a copy of our Bylaws by writing to the Secretary at this address.

**Meetings of Our Independent Directors and Communications with our Board of Directors**

During meetings of the Board of Directors, the independent directors meet regularly in an executive session without management or management directors present. The purpose of these executive sessions is to promote open and candid discussion among the non-management directors. Our Board of Directors recommends that stockholders and other interested parties initiate communications with our Board of Directors, the independent directors, the Chair, or any committee of our Board of Directors in writing to the attention of our Secretary, Decoy Therapeutics Inc., 2450 Holcombe Blvd., Suite X, Houston, TX 77021. This process will assist our Board of Directors in reviewing and responding to stockholder communications in an appropriate manner. Our Board of Directors has instructed our Secretary to review such correspondence and, at his discretion, not to forward items if he deems them to be of a commercial or frivolous nature or otherwise inappropriate for our Board of Directors' consideration such as spam,

------

[**<u>**Table of Contents**</u>**](#toc_page)

junk mail and mass mailings, product complaints, personal employee complaints, product inquiries, new product suggestions, resumes and other forms of job inquiries, surveys, business solicitations, or advertisements.

**2025 Director Compensation**

The following table sets forth the compensation to the Company's non-employee directors that was paid or accrued by the Company in 2025 pursuant to the non-employee director compensation policy described below.

---

| | | | |
|:---|:---|:---|:---|
| **Name(1)** | **Fees Earned<br>or Paid in<br>Cash(2)** | **Stock<br>Options(3)** | **Total** |
| Tess Burleson | $33500 | $— | $33500 |
| Arnold C. Hanish | $40000 | $— | $40000 |
| Paul Lammers | $30000 | $— | $30000 |
| Jonathan Lieber | $33500 | $— | $33500 |
| Bruce J. McCreedy(4) | $33505 | $— | $33505 |
| William K. McVicar | $50000 | $— | $50000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Mr. Arthur is not included in this table as he served as the Company's Chief Executive Officer through August 17, 2025; any fees earned by Mr. Arthur for service as a director following his cessation as Chief Executive Officer, and any compensation paid pursuant to the Consulting Agreement, are included in the Summary Compensation Table. Mr. Pierce is not included in this table as he is the Company's Chief Executive Officer and receives no additional compensation for his service as a director.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The amounts listed in this column represent the retainer paid to each director for their service on the Board of Directors and any committees on which they served during 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)No stock options granted to directors in year 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Dr. McCreedy resigned from the Board of Directors on November 12, 2025 in connection with the closing of the Merger. The amounts shown represent fees paid to Dr. McCreedy during the portion of 2025 in which he served as a director.

***Director Compensation Arrangements***

The Company's non-employee director compensation is comprised of cash compensation and equity compensation. Further, the Company reimburses all of its non-employee directors for their reasonable expenses incurred in attending meetings of the Board of Directors and committees of the Board of Directors.

Generally, the Board of Directors believes that the level of director compensation should be based on time spent carrying out Board of Directors and committee responsibilities and be competitive with comparable companies. In addition, the Board of Directors believes that a significant portion of director compensation should align director interests with the long-term interests of stockholders. The Board of Directors makes changes in its director compensation practices only upon the recommendation of the Compensation Committee, and discussion and approval by the Board of Directors.

The Board of Directors, following the Compensation Committee's recommendation, has approved the compensation of the Company's non-employee directors, as described below. The Compensation Committee believes that its non-employee director compensation remains aligned with director compensation practices at the Company's peer companies while considering the ongoing cash constraints of the Company.

*Cash Compensation* 

------

[**<u>**Table of Contents**</u>**](#toc_page)

On February 20, 2024, the Board of Directors approved a reduction in cash compensation payable to its non-employee directors. Effective as of April 1, 2024, non-employee directors receive an annual cash retainer of $30,000 (previously $40,000) for their Board of Directors service. In addition, the Chair of the Board of Directors receives an additional annual cash retainer of $20,000 (previously $40,000), the Chair of the Audit Committee of the Board of Directors receives an additional annual cash retainer of $10,000 (previously $20,000), and members of the Audit Committee receive an additional annual cash retainer of $3,500 (previously $7,500). No additional cash retainers are paid for serving as a Chair or member of the Compensation Committee of the Board of Directors or the Nominating and Corporate Governance Committee of the Board of Directors.

***Outstanding Equity Awards***

The following table provides information regarding the aggregate number of shares subject to outstanding stock options held by non-employee directors as of December 31, 2025. All share amounts have been adjusted to reflect the 1-for-15 reverse stock split effected on August 15, 2025 and the 1-for-12 reverse stock split effected on March 6, 2026.

---

| | | |
|:---|:---|:---|
| **Name(1)** | **Number of<br>Shares<br>Subject to<br>Outstanding<br>Stock Options** | **Number of<br>Restricted<br>Shares of<br>Common<br>Stock** |
| Tess Burleson | 16 | 1 |
| Arnold C. Hanish | 16 | 1 |
| Paul Lammers | 16 | 1 |
| Jonathan Lieber | 16 | 1 |
| Bruce J. McCreedy(2) | 16 | 1 |
| William K. McVicar | 16 | 1 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Mr. Arthur is not included in this table as he served as the Company's Chief Executive Officer through August 17, 2025; any fees earned by Mr. Arthur for service as a director following his cessation as Chief Executive Officer, and any compensation paid pursuant to the Consulting Agreement, are included in the Summary Compensation Table. Mr. Pierce is not included in this table as he is the Company's Chief Executive Officer and receives no additional compensation for his service as a director.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Dr. McCreedy resigned from the Board of Directors on November 12, 2025 in connection with the closing of the Merger. The outstanding equity awards shown for Dr. McCreedy represent vested options that remained outstanding as of December 31, 2025 and exercisable within the post-termination exercise period applicable to his awards under the Salarius Pharmaceuticals 2015 Equity Incentive Plan.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**EXECUTIVE COMPENSATION** 

The Company's "named executive officers" for the year ended December 31, 2025 were:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Frederick E. Pierce, the Company's Chief Executive Officer (since November 12, 2025);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Mark J. Rosenblum, the Company's Executive Vice President of Finance and Chief Financial Officer, and , from August 17 to November 12, 2025, its Acting Chief Executive Officer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•David J. Arthur, the Company's former President and Chief Executive Officer (until August 17, 2025);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Barbara Hibner, Ph.D., the Company's Chief Scientific Officer (since November 12, 2025); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Peter Marschel, the Company's Chief Business Officer (since November 12, 2025).

On February 20, 2024, the Company entered into a separation and release agreement with Mr. Arthur, as more fully described below under "Employment and Separation Agreements." Mr. Arthur continued to provide services to the Company following his cessation of employment pursuant to a consulting arrangement, with Mr. Arthur's service as Chief Executive Officer thereunder ending on August 17, 2025. On August 17, 2025, Mr. Arthur resigned as Chief Executive Officer and the Board of Directors appointed Mr. Rosenblum as Acting Chief Executive Officer and designated him as the Company's principal executive officer, in each case effective as of that date, with Mr. Rosenblum continuing to serve in his role as Executive Vice President and Chief Financial Officer. Mr. Rosenblum continued to serve as the Company's Acting Chief Executive Officer and principal executive officer until November 12, 2025, at which time, in connection with the closing of the Merger, Mr. Pierce was appointed as the Company's Chief Executive Officer.

On November 18, 2025, the Company entered into executive employment agreements with each of Mr. Pierce, Dr. Hibner and Mr. Marschel, as more fully described below under "Employment and Separation Agreements."

Additionally, on February 20, 2024, the Company and Mr. Rosenblum entered into an Amendment to Executive Employment Agreement, which amended that certain Executive Employment Agreement, dated April 24, 2020, by and between the Company and Mr. Rosenblum, solely to provide Mr. Rosenblum with the option to receive any severance that may be owed to him pursuant to Section 5(c)(i) thereof in equal installments over a period of time or in a lump-sum amount.

Investors are encouraged to read the compensation discussion below under "Narrative Disclosure to Summary Compensation Table" in conjunction with the summary compensation tables and related notes.

**Summary Compensation Table**

The following table sets forth compensation for services rendered in all capacities to the Company for the years ended December 31, 2025 and 2024 for the Company's named executive officers. Mr. Pierce, Dr. Hibner and Mr. Marschel commenced service as executive officers of the Company on November 12, 2025 in connection with the closing of the Merger; accordingly, only compensation paid by the Company to such individuals in respect of fiscal year 2025 is presented in this table, and no amounts are presented for fiscal year 2024.

------

[**<u>**Table of Contents**</u>**](#toc_page)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year** | **Salary ($)** | **Bonus ($)** | **Stock**<br>**Awards**<br>**($)(2)** | **Option**<br>**Awards**<br>**($)(3)** | **All Other**<br>**Comp ($)** | **Total ($)** |
| Frederick E. Pierce Chief Executive Officer(1) | 2025 | 29607 |  |  | 195429 |  | 225036 |
| Mark J. Rosenblum Executive Vice President, Finance, Chief Financial Officer and Former Acting Chief Executive Officer (4) | 2025 | 330000 | $225000 |  |  | 14000 | 569000 |
|  | 2024 | 330000 |  |  | 11372 | 9050 | 350422 |
| David J. Arthur Former President and Chief Executive Officer(5) | 2025 | 68300 |  |  |  | 37930 | 106229 |
|  | 2024 | 176153 |  |  | 8265 | 550032 | 734450 |
| Barbara Hibner, Ph.D. Chief Scientific Officer(6) | 2025 | 29607 |  |  | 195429 |  | 225036 |
| Peter Marschel Chief Business Officer(6) | 2025 | 29607 |  |  | 195429 | 45 | 225081 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Mr. Pierce commenced service as the Company's Chief Executive Officer on November 12, 2025 in connection with the closing of the Merger. The amounts shown reflect compensation earned by Mr. Pierce from the Company for the period from November 12, 2025 through December 31, 2025. Mr. Pierce receives no additional compensation for his service as a director.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The amounts reported in this column represent the grant date fair value of the restricted stock granted, calculated in accordance with FASB ASC Topic 718 using the close price of the Company's common stock on the grant date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)The amounts reported in this column represent the grant date fair value of stock options using the Black-Scholes option-pricing model computed in accordance with FASB ASC Topic 718. See Note 8 to the Company's consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year-ended December 31, 2025 for the assumptions used in such valuation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Mr. Rosenblum served as Legacy Salarius' Executive Vice President and Chief Financial Officer since September 2019, and as the Company's Acting Chief Executive Officer from August 17 to November 12, 2025. The amounts reported in the Bonus column for Mr. Rosenblum include a $225,000 transaction bonus paid in 2025 to Mr. Rosenblum in connection with the closing of the Merger.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Mr. Arthur served as Legacy Salarius' President and Chief Executive Officer and a director since July 2019. Mr. Arthur's full-time employment with Legacy Salarius ended, effective February 2024, but he continued to serve as Chief Executive Officer of Legacy Salarius in his role as a part-time consultant until August 17, 2025. The amounts reported for Mr. Arthur for 2025 include (i) consulting fees paid pursuant to the Consulting Agreement in respect of services rendered through August 17, 2025; (ii) reimbursement of COBRA premiums paid pursuant to the Separation Agreement, if any; and (iii) non-employee director fees paid for his service on the Board of Directors in 2025.The amount shown for Mr. Arthur for 2024 in the "Salary" column comprises (i) $68,750 in salary earned and paid to Mr. Arthur in 2024 pursuant to his employment agreement with the Company prior to the termination of his employment on February 20, 2024 and (ii) $107,403 in consulting fees earned and paid to Mr. Arthur in 2024 pursuant to the Consulting Agreement. The 2024 amount in the "All Other Compensation" column includes Mr. Arthur's severance payment of $500,000, unused paid time off of $5,341 and COBRA premiums of $19,691 paid in 2024 pursuant to that certain Separation and Release Agreement, dated February 20, 2024, between the Company and Mr. Arthur, $2,500 in matching contributions by the Company pursuant to its 401(k) plan, and $22,500 of director fees earned in 2024 following Mr. Arthur's termination of employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Dr. Hibner and Mr. Marschel commenced service as executive officers of the Company on November 12, 2025 in connection with the closing of the Merger. The amounts shown reflect compensation earned by each of them from the Company for the period from November 12, 2025 through December 31, 2025.

**Narrative Disclosure to Summary Compensation Table**

In the process of determining compensation for the Company's named executive officers, the Compensation Committee considers the current financial position of the Company, the strategic goals of the Company, and the performance of each of the Company's named executive officers. In addition, from time to time, the Compensation

------

[**<u>**Table of Contents**</u>**](#toc_page)

Committee considers the various components (described below) of the Company's compensation program for executives in relation to compensation paid by other public companies, compensation data, their historical review of all executive officer compensation, and recommendations from the Company's Chief Executive Officer (other than for his own salary). The Compensation Committee has the sole authority to select, compensate and terminate its external advisors.

The Compensation Committee utilizes the following components of compensation (described further below) to strike an appropriate balance between promoting sustainable and excellent performance and discouraging any excessive risk-taking behavior:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Base Salary;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Non-equity incentive plan compensation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Annual long-term equity compensation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Personal benefits and perquisites; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Acceleration and severance agreements tied to changes in control of the Company.

*Base Salaries*

The Company's named executive officers receive base salaries as set forth in their respective employment or consulting agreements. Each named executive officer is eligible for annual raises subject to review and approval of the Compensation Committee. Mr. Rosenblum's base salary was $330,000 for 2025. Following the closing of the Merger, pursuant to employment agreements entered into on November 18, 2025, each of Mr. Pierce, Dr. Hibner and Mr. Marschel receive an annual base salary of $225,000. Mr. Arthur received compensation for his services as the Company's Chief Executive Officer pursuant to the Consulting Agreement and the Consulting Agreement Amendment thereto described below under "Employment and Separation Agreements" until August 17, 2025.

*Non-Equity Incentive Plan Compensation*

Target bonuses are reviewed annually and established as a percentage of the executives' base salaries, generally based upon seniority of the officer and targeted at or near the median of the peer group (with reference to the Company's corporate compensation philosophy) and relevant survey data. Each year, the Compensation Committee establishes corporate and individual objectives and respective target percentages, taking into account recommendations from the Company's Chief Executive Officer as it relates to executive positions other than the Chief Executive Officer's compensation. The Company's Chief Executive Officer's target bonus is set by the Compensation Committee to align entirely with the Company's overall corporate objectives. At the end of each fiscal year-end, the Company's Chief Executive Officer provides the Compensation Committee with a written evaluation showing actual performance as compared to corporate and/or individual objectives, and the Compensation Committee uses that information, along with the overall corporate performance, to determine what percentage of each executive's bonus target will be paid out as a bonus for that year. Overall, the Compensation Committee seeks to establish the corporate and individual functional goals to be highly challenging yet attainable.

Mr. Rosenblum's target bonus for both 2025 and 2024 as a percentage of base salary was 35%. Each of Mr. Pierce, Dr. Hibner and Mr. Marschel is eligible to receive a target annual bonus of 35% of his or her base salary, to be earned based upon the achievement of performance objectives to be determined by the Compensation Committee.

In addition to the annual bonus program described above, on October 21, 2025, the Board of Directors approved the grant of a one-time cash transaction bonus to Mr. Rosenblum in the amount of $225,000, payable following the closing of the Merger and subject to his continued employment with the Company through the closing of the Merger. The Merger closed on November 12, 2025, and the transaction bonus was paid to Mr. Rosenblum in accordance with its terms.

*Long-Term Equity Compensation*

------

[**<u>**Table of Contents**</u>**](#toc_page)

The Company designed its long-term equity grant program to further align the interests of its executives with those of its stockholders and to reward the executives' longer-term performance. Historically, the Compensation Committee has granted stock options, although from time to time, to further increase the emphasis on compensation tied to performance, the Compensation Committee may grant other equity awards as allowed by the Company's equity compensation plans. The Compensation Committee may grant stock options, restricted stock, restricted stock units and similar equity awards permitted under the Company's plans based on its judgment as to whether the complete compensation packages to the Company's executives, including prior equity awards, are appropriate and sufficient to retain and incentivize the executives and whether the grants balance long-term versus short-term compensation. The Compensation Committee also considers the Company's overall performance as well as the individual performance of each of the Company's named executive officers, the potential dilutive effect of restricted stock awards, the dilutive and overhang effect of the equity awards, and recommendations from the Chief Executive Officer (other than with respect to his own equity awards).

Stock options are granted with an exercise price equal to the fair market value of the Company's common stock on the date of grant. Restricted stock is granted at the closing price of the Company's common stock on the grant date.

No awards were granted to named executive officers in 2025 by the Company.

In connection with the closing of the Merger on November 12, 2025, each outstanding Legacy Decoy stock option held by each of Mr. Pierce, Dr. Hibner and Mr. Marschel was assumed by the Company and converted into an option to purchase shares of the Company's common stock in accordance with the exchange ratio set forth in the Merger Agreement.

*Personal Benefits and Perquisites*

All of the Company's executives are eligible to participate in the Company's employee benefit plans, including medical, dental, vision, life insurance, short-term and long-term disability insurance, flexible spending accounts, 401(k), and an employee stock purchase program. These plans are available to all full-time employees. In keeping with the Company's philosophy to provide total compensation that is competitive within the Company's industry, the Company offers limited personal benefits and perquisites to its executive officers. You can find more information on the amounts paid for these perquisites to or on behalf of the Company's named executive officers in the Company's Summary Compensation Table.

*Nonqualified Deferred Compensation*

None of the Company's named executive officers participates in or has account balances in nonqualified defined contribution plans or other nonqualified deferred compensation plans maintained by the Company. The Board of Directors may elect to provide its officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in the Company's best interests.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Outstanding Equity Awards at fiscal year end**

The following table presents certain information concerning equity awards held by the Company's named executive officers as of December 31, 2025. All share and per share amounts have been adjusted to reflect the 1-for-15 reverse stock split effected on August 15, 2025 and the 1-for-12 reverse stock split effected on March 6, 2026. Options granted by Legacy Decoy prior to the closing of the Merger that were assumed by the Company at the closing of the Merger are presented on an as-converted basis using the exchange ratio set forth in the Merger Agreement.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** |
| **Name** | **Grant Date** | **Number of<br>securities<br>underlying<br>unexercised<br>options —<br>exercisable** | **Number of<br>securities<br>underlying<br>unexercised<br>options —<br>unexercisable** | **Option<br>Exercise<br>Price ($)** | **Option<br>Expiration<br>Date** | **Number of<br>shares or<br>units of stock<br>that have not<br>vested** <sup>(4)</sup> | **Market value<br>of shares or<br>units of stock<br>that have not<br>vested<br>($)**<sup>(4)</sup> |
| Frederick E. Pierce<sup>(1)</sup> | 4/1/2022 | 422 |  | 59.28 | 4/1/2032 |  |  |
|  | 7/16/2025 | 352 |  | 603.24 | 7/16/2035 |  |  |
|  | 7/16/2025<sup>(2)</sup> | 72 | 270 | 603.24 | 7/16/2035 |  |  |
| Mark J. Rosenblum |  |  |  |  |  |  |  |
|  | 7/14/2020 | 1 |  | 47520 | 7/13/2030 |  |  |
|  | 12/2/2020 | 2 |  | 26640 | 12/1/2030 |  |  |
|  | 1/20/2022<sup>(3)</sup> | 4 | 1 | 17280 | 1/19/2032 |  |  |
|  | 1/3/2023<sup>(4)</sup> |  |  |  |  | 2 | 15.57 |
|  | 2/20/2024<sup>(3)</sup> | 6 | 10 | 822.38 | 2/20/2034 |  |  |
| David J. Arthur<sup>(5)</sup> |  |  |  |  |  |  |  |
|  | 3/23/2020 | 1 |  | 21960 | 3/22/2030 |  |  |
|  | 7/14/2020 | 9 |  | 47250 | 7/13/2030 |  |  |
|  | 12/2/2020 | 7 |  | 26640 | 12/1/2030 |  |  |
|  | 1/20/2022<sup>(3)</sup> | 11 | 2 | 17280 | 1/19/2032 |  |  |
|  | 1/3/2023<sup>(4)</sup> |  |  |  |  | 4 | 31.14 |
|  | 4/11/2024<sup>(6)</sup> | 14 |  | 734.4 | 4/11/2034 |  |  |
| Barbara Hibner, Ph.D.<sup>(1)</sup> | 4/1/2022 | 422 |  | 59.28 | 4/1/2032 |  |  |
|  | 7/16/2025 | 352 |  | 603.24 | 7/16/2035 |  |  |
|  | 7/16/2025<sup>(2)</sup> | 72 | 270 | 603.24 | 7/16/2035 |  |  |
| Peter Marschel<sup>(1)</sup> | 4/1/2022 | 422 |  | 59.28 | 4/1/2032 |  |  |
|  | 7/16/2025 | 352 |  | 603.24 | 7/16/2035 |  |  |
|  | 7/16/2025<sup>(2)</sup> | 72 | 270 | 603.24 | 7/16/2035 |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)All options shown for Mr. Pierce, Dr. Hibner and Mr. Marschel were originally granted by Legacy Decoy and were assumed by the Company in connection with the closing of the Merger and converted into options to purchase shares of the Company's common stock in accordance with the exchange ratio set forth in the Merger Agreement. Unless otherwise noted, the options granted on April 1, 2022 are fully vested and the options granted on July 16, 2025 are fully vested.

------

[**<u>**Table of Contents**</u>**](#toc_page)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Vesting of these options occurs over two years from the original date of grant with 1/24th vesting monthly, subject to continued service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Represents options of which 25% became exercisable on the one-year anniversary of the grant date, with the remainder becoming exercisable in equal 1/36th installments on the last day of each calendar month thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)25% of the shares of restricted stock vested on January 2, 2024 and 1/36 of the remaining shares of restricted stock will vest on monthly anniversaries thereafter. The market value of unvested shares of restricted stock is based on the closing market price of the Company's common stock on December 31, 2025 of $7.7859.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Mr. Arthur's service as Chief Executive Officer terminated on August 17, 2025 and he continues to serve as a director. Pursuant to the Notice of Stock Option Amendment, dated February 20, 2024, the post-termination exercise period for Mr. Arthur's options granted on September 10, 2019, March 23, 2020, July 14, 2020, December 2, 2020 and January 20, 2022 was extended from 90 days to 18 months upon the termination of his "Continuous Service" (as defined in the Salarius Pharmaceuticals 2015 Equity Incentive Plan) for any reason other than for "Cause" (as defined in such plan), but not beyond the term of the applicable stock option, and subject to earlier termination as provided under such plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)100% of the options became exercisable on the one-year anniversary of the grant date.

**Employment and Separation Agreements**

Below are descriptions of the employment or separation agreements with the Company's named executive officers. Furthermore, each of the Company's executive officers has executed a form of the Company's standard proprietary information and inventions assignment agreement.

*Pierce, Hibner and Marschel Employment Agreements*

On November 18, 2025, the Company entered into an executive employment agreement with each of Mr. Pierce, Dr. Hibner and Mr. Marschel (each, an "Employment Agreement" and, collectively, the "Employment Agreements"). Under each Employment Agreement, the applicable executive's annual base salary is $225,000 and such executive is eligible to receive a target annual bonus of 35% of his or her base salary, to be earned based upon the achievement of performance objectives to be determined by the Compensation Committee. Each executive is also eligible to participate in any Company-sponsored benefit plans and programs, including medical, dental, life and disability insurance, holidays and other perquisites, at a level appropriate for his or her position and duties and to the extent that the Company makes such benefits generally available to executives of the Company.

If an Employment Agreement is terminated by the Company for "cause", or if employment is terminated as a result of death or "disability" or the applicable executive's resignation without "good reason," the Company will pay such executive (i) any unpaid base salary accrued up to the date of termination, (ii) accrued but unused vacation, (iii) benefits payable to such executive pursuant to the terms and conditions of any benefit plan or program in which such executive participated during the term of employment, and (iv) unreimbursed business expenses.

If the Company terminates any executive's employment other than for "cause," or in the event any executive terminates his or her employment with "good reason," then such executive will receive (i) severance pay in an amount equal to $225,000 and (ii) a monthly payment as a reimbursement that in the aggregate is equal to nine months of COBRA benefits at active employee rates (together, the "Severance Payments"). Each executive is required to deliver a formal release of all claims prior to, and as a condition of, his or her receipt of any of the Severance Payments or other post-employment benefits described in the applicable Employment Agreement. The definitions of "cause" and "good reason" are set forth in the Employment Agreements.

*David J. Arthur Separation Agreement*

On February 20, 2024 (the "Separation Date"), the Company entered into a Confidential Separation Agreement and General Release (the "Separation Agreement") with David J. Arthur, the Company's then-President and Chief Executive Officer, which provided for Mr. Arthur's separation of employment, effective as of the Separation Date. Under the Separation Agreement, and in full satisfaction of the Company's obligations set forth in Section 5(c)(ii) of Mr. Arthur's prior employment agreement, the Company paid Mr. Arthur $500,000 in a lump sum, representing an amount equal to twelve months of Mr. Arthur's then-current base salary, and agreed to reimburse Mr. Arthur, subject

------

[**<u>**Table of Contents**</u>**](#toc_page)

to specified conditions, for his cost of continuation of group healthcare coverage under the Company's group medical and dental plans pursuant to Section 4980B of the Internal Revenue Code for the shorter of (1) twelve months following the Separation Date, or (2) until the date Mr. Arthur secured reasonably comparable coverage with another employer. The Separation Agreement also contains customary mutual releases, confidentiality, non-disparagement and return of property provisions.

Mr. Arthur continued to serve as the Company's principal executive officer and provided services to the Company in such capacity pursuant to a Consulting Agreement, dated February 20, 2024 (the "Consulting Agreement"). Pursuant to the Consulting Agreement, Mr. Arthur was required to devote at least one-fourth (1/4) of his time on a weekly basis (on average 10 or more hours per week) to performing the services set forth in the Consulting Agreement. In exchange for Mr. Arthur's services as set forth in the Consulting Agreement, Mr. Arthur received $10,417 per month. The term of the Consulting Agreement was set to expire on February 20, 2025, unless earlier terminated by either party in accordance with the terms of the Consulting Agreement. On February 20, 2025, the Company entered into the First Amendment to the Consulting Agreement (the "Consulting Agreement Amendment"). In exchange for Mr. Arthur's services as set forth in the Consulting Agreement Amendment, Mr. Arthur received $500 per hour. Mr. Arthur's service as principal executive officer under the Consulting Agreement (as amended) ceased effective August 17, 2025 upon the appointment of Mr. Rosenblum as Acting Chief Executive Officer.

In addition, on the Separation Date, the Company entered into a Notice of Stock Option Amendment with Mr. Arthur (the "Notice of Stock Option Amendment"), pursuant to which the Board of Directors amended the stock options to purchase shares of common stock granted to Mr. Arthur on September 10, 2019, March 23, 2020, July 14, 2020, December 2, 2020 and January 20, 2022 pursuant to the Company's 2015 Equity Incentive Plan (the "Plan") to extend the post-termination exercise period from 90 days to 18 months upon the termination of Mr. Arthur's "Continuous Service" (as defined in the Plan) for any reason other than for "Cause" (as defined in the Plan), but not beyond the term of the applicable stock option, and subject to earlier termination (such as in connection with a "Corporate Transaction" (as defined in the Plan) as provided under the Plan).

Mr. Arthur also entered into an updated indemnification agreement with the Company (the "Indemnification Agreement") to reflect his change in status from an employee of the Company to a consultant.

*Mark J. Rosenblum*

On April 24, 2020, the Company entered into an Executive Employment Agreement with Mark J. Rosenblum, its Executive Vice President of Finance and Chief Financial Officer (the "Rosenblum Agreement"). In November 2022, Mr. Rosenblum's base salary was increased to $330,000, which increase became effective January 1, 2023. On February 20, 2024, the Company entered into an amendment to the Rosenblum Agreement to provide Mr. Rosenblum with the option to receive any severance that may be owed to him pursuant to Section 5(c)(i) thereof in equal installments over a period of time or in a lump-sum amount.

**Clawback Policy**

The Company has a compensation recoupment, or clawback policy, which the Company adopted to comply with Nasdaq listing standards implementing Exchange Act Rule 10D-1. The clawback policy includes mandatory recoupment of excess incentive-based compensation received by a covered executive (including the named executive officers) on or after October 2, 2023 in the event of a restatement of the Company's financial statements due to material non-compliance with any financial reporting requirement under federal securities laws, as required by Exchange Act Rule 10D-1.

**Additional Narrative Disclosure: Termination-Based Compensation**

The Rosenblum Agreement provides that, so long as Mr. Rosenblum executes a release and settlement agreement with the Company, and subject to applicable withholdings, he would be entitled to receive a cash severance and an amount for premium payments under COBRA. Under the Rosenblum Agreement, the cash severance is equal to 9 months and if Mr. Rosenblum elects continuation coverage under COBRA or state law equivalent or enrollment in an individual marketplace, the Company will pay him an amount equal to 9 months' worth of total premium payments (or until the

------

[**<u>**Table of Contents**</u>**](#toc_page)

date the executive secures reasonably comparable coverage with another employer, if sooner). These payments to Mr. Rosenblum are required to be made upon the following termination events:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In the event the Company or a successor entity terminates the executive's employment for any reason other than a termination for Cause, or in connection with death, a permanent disability, or the Company's dissolution; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In the event that, within the 18-month period following a Change in Control, the Company or a successor entity terminates the executive's employment for any reason other than a termination for Cause, or in connection with death, a permanent disability, or the Company's dissolution, or if the executive terminates his employment for Good Reason.

The definitions of "Cause", "Good Reason" and Change in Control are set forth in the Rosenblum Agreement.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Pay Versus Performance** 

In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act), we provide the following disclosure regarding executive compensation for our principal executive officer ("PEO") and Non-PEO named executive officers ("NEOs") and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.

**Pay Versus Performance Table** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Year** | **Summary<br>Compensation<br>Table for<br>PEO (Mr. Arthur)**<sup>(1)</sup> | **Compensation<br>Actually <br>Paid to<br>PEO (Mr. Arthur)**<sup>(2)(3)</sup> | **Summary<br>Compensation<br>Table for<br>PEO (Mr. Rosenblum)**<sup>(1)</sup> | **Compensation<br>Actually <br>Paid to<br>PEO (Mr. Rosenblum)**<sup>(2)(3)</sup> | **Summary<br>Compensation<br>Table for<br>PEO (Mr. Pierce)**<sup>(1)</sup> | **Compensation<br>Actually <br>Paid to<br>PEO (Mr. Pierce)**<sup>(2)(3)</sup> |
| 2025 | $106230 | $106223 | $569000 | $567967 | $225036 | $124488 |
| 2024 | $734450 | $727586 | $— | $— | $— | $— |
| 2023 | $544600 | $516927 | $— | $— | $— | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Average<br>Summary<br>Compensation <br>Table Totals<br>for non-PEO<br>NEOs**<sup>(1)</sup> | **Average<br>Compensation<br>Actually<br>Paid to<br>non-PEO<br>NEO**<sup>(2)(3)</sup> | **Value of<br>Initial<br>Fixed $100<br>Investment<br>Based On: <br>Total<br>Shareholder<br>Return** | **Net Loss <br>(in millions)** |
| 2025 | $225059 | $124511 | $0.35 | $12.52 |
| 2024 | $350422 | $343233 | $15.03 | $5.58 |
| 2023 | $355760 | $345284 | $42.48 | $12.54 |

---

(1)Reflects the amount reported in the "Total" column of the Summary Compensation Table for each of David Arthur, Mark Rosenblum, and Frederick Pierce for each corresponding year in which they served as PEO. See "Executive Compensation - Summary Compensation Table" and "Executive Compensation - Summary Compensation Table" in our 2025 Definitive Proxy Statement filed with the SEC on November 7, 2025.The PEO for 2025 is David Arthur, Mark Rosenblum and Frederick Pierce. The PEO for 2024 and 2023 is David Arthur. The Non-PEO NEO for whom the average compensation is presented in the table for 2025 is Barbara Hibner and Peter Marschel and for 2024 and 2023 is Mark Rosenblum.

(2)The amounts shown as Compensation Actually Paid ("CAP") have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually realized or received by the Company's PEOs and Non-PEO NEOs. These amounts reflect total compensation as set forth in the Summary Compensation Table for each year, adjusted as described in footnote 3 below.

(3)CAP reflects the exclusions and inclusions for the PEOs and the Non-PEO NEOs set forth below. Amounts excluded, which are set forth in the "Minus Stock and Option Awards from Summ. Comp. Table" columns below, represent the stock awards and option awards reported in the Stock Awards and Option Awards columns of the Summary Compensation Table for each applicable year. Amounts added back to determine CAP are made up of the following components which are set forth in the table below, as applicable: (i) the fair value as of the end of the fiscal year of outstanding and unvested equity awards granted in that year; (ii) the change in fair value during the year of equity awards granted in prior years that remained outstanding and unvested at the end of the year; (iii) the fair value as of the vesting date of equity awards that were granted and vested in that year; and (iv) the change in fair value during the year through the vesting date of equity awards granted in prior years that vested during that year. The fair value at the end of the prior year of awards granted in any prior year that failed to meet applicable vesting conditions during the covered year are subtracted. Equity values are calculated in accordance with ASC Topic 718.

------

[**<u>**Table of Contents**</u>**](#toc_page)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year** | **Summary<br>Comp. Table<br>Total for<br>PEO** | **Minus Stock<br>and Option<br>Awards from<br>Summ.<br>Comp. Table** | **Plus Year-<br>End Equity<br>Value of<br>Unvested<br>Awards<br>Granted<br>During Year** | **Plus Change<br>in Value of <br>Unvested<br>Awards<br>Granted in<br>Prior Years** | **Plus Value of<br>Awards<br>Granted <br>and Vested <br>During Year** | **Plus Change<br>in Value of<br>Prior Years'<br>Awards<br>Vested<br>During Year** | **Comp.<br>Actually <br>Paid to PEO** |
| 2025 | $900266 | $195429 | $189 | $(11) | $94692 | $(1029) | $798678 |
| 2024 | $734450 | $8265 | $1522 | $(163) | $— | $42 | $727586 |
| 2023 | $544600 | $31400 | $13000 | $(10395) | $— | $1122 | $516927 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year** | **Average Summary<br>Comp. Table<br>Total for<br>Other NEOs** | **Minus Average Stock<br>and Option<br>Awards from<br>Summ.<br>Comp. Table** | **Plus Average Year-<br>End Equity <br>Value of<br>Unvested <br>Awards<br>Granted <br>During Year** | **Plus Average Change <br>in Value of <br>Unvested <br>Awards<br>Granted in<br>Prior Years** | **Plus Average Value of<br>Awards<br>Granted<br>and Vested<br>During Year** | **Plus Average Change<br>in Value of<br>Prior Years'<br>Awards<br>Vested<br>During Year** | **Average Comp. <br>Actually<br>Paid to <br>Other NEOs** |
| 2025 | $225059 | $195429 | $189 | $— | $— | $94692 | $124511 |
| 2024 | $350422 | $11372 | $4230 | $(65) | $— | $18 | $343233 |
| 2023 | $355760 | $12560 | $5200 | $(3791) | $— | $675 | $345284 |

---

**Pay Versus Performance Narrative Disclosure** 

In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table on CAP and each of total stockholder return ("TSR") and net loss.

We do not utilize TSR and net loss in our executive compensation program. However, we do utilize several other performance measures to align executive compensation with our performance. As described in more detail above in the section of Summary Compensation Tables and Employment Agreements, part of the compensation our NEOs are eligible to receive consists of annual performance-based cash bonuses that are designed to provide appropriate incentives to our executives to achieve defined annual corporate goals and to reward our executives for individual achievement towards these goals, subject to certain employment criteria. Additionally, we view stock options, which are an integral part of our executive compensation program, as related to company performance although not directly tied to TSR, because they provide value only if the market price of our common stock increases, and if the executive officer continues in our employment over the vesting period. These stock option awards strongly align our executive officers' interests with those of our stockholders by providing a continuing financial incentive to maximize long-term value for our stockholders and by encouraging our executive officers to continue in our employment for the long-term.

With respect to net income, specifically, because we are not a commercial-stage company, we did not have any revenue during the periods presented, other than revenue associated with grants. Consequently, our company does not consider net loss as a performance measure for our executive compensation program. In 2025, our net loss increased from 2024. This increase was primarily due to the Merger closed on November 12, 2025.

The following graph illustrates the relationship during 2023-2025 of the CAP for our PEOs and non-PEO NEOs as calculated pursuant to SEC rules to our TSR assuming a $100 investment in our stock on December 31, 2022.

------

[**<u>**Table of Contents**</u>**](#toc_page)

![img45420450_0.jpg](img45420450_0.jpg)

The following graph illustrates the relationship during 2023-2025 of the CAP for our CEOs and other NEOs as calculated pursuant to SEC rules to our net loss.

![img45420450_1.jpg](img45420450_1.jpg)

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Equity Compensation Plan Information** 

The following table summarizes our equity compensation plan information as of December 31, 2025. All share and per share amounts have been adjusted to reflect the 1-for-15 reverse stock split effected on August 15, 2025 and the 1-for-12 reverse stock split effected on March 6, 2026.

---

| | | | |
|:---|:---|:---|:---|
| **Plan Category** | **(a) Number of<br>Securities to<br>be Issued<br>Upon Exercise<br>of Outstanding<br>Options and<br>Restricted<br>Stock Units** | **(b) Weighted<br>Average<br>Exercise Price<br>of Outstanding<br>Equity Stock<br>Options ($)** | **(c) Number of<br>Securities<br>Remaining<br>Available for<br>Future<br>Issuance<br>Under Equity<br>Compensation<br>Plans<br>(Excluding<br>Securities<br>Reflected in<br>Column (a))** |
| Equity compensation plans approved by stockholders |  |  |  |
| 2015 Equity Incentive Plan(1) | 155 | 104.37 |  |
| 2020 Equity Incentive Plan(2) | 13548 | 376.33 |  |
| 2015 Employee Stock Purchase Plan(3) |  |  |  |
| Equity compensation plans not approved by stockholders |  |  |  |
| **Total** | 13703 |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The 2015 Equity Incentive Plan expired by its terms in January 2025. No additional awards may be granted under the 2015 Plan; however, outstanding awards previously granted under the 2015 Plan continue to be exercisable in accordance with their terms. No new awards were granted under the 2015 Plan during the year ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The 2020 Equity Incentive Plan was originally adopted by Legacy Decoy and was assumed by the Company in connection with the closing of the Merger on November 12, 2025. Each outstanding option under the 2020 Plan was converted into an option to purchase shares of the Company's common stock in accordance with the exchange ratio set forth in the Merger Agreement. No shares remain available for future issuance under the 2020 Plan following the Merger assumption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)The 2015 ESPP was originally adopted by Salarius Pharmaceuticals, Inc. in 2015. The evergreen share increase provision of the 2015 ESPP ended on January 1, 2024, and accordingly no automatic increases to the share reserve occurred on or after such date.

**Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information** 

The Company does not have any formal policy that requires the Company to grant, or avoid granting, equity-based compensation to its executive officers at certain times. Consistent with its annual compensation cycle, the Compensation Committee has for several years granted annual equity awards to its executive officers in February of each year. The timing of any equity grants to executive officers in connection with new hires, promotions, or other non-routine grants is tied to the event giving rise to the award (such as an executive officer's commencement of employment or promotion effective date). As a result, in all cases, the timing of grants of equity awards, including stock options, occurs independent of the release of any material nonpublic information, and the Company does not time the disclosure of material nonpublic information for the purpose of affecting the value of equity-based compensation.

------

[**<u>**Table of Contents**</u>**](#toc_page)

No stock options were issued to the Company's executive management or members of the Board of Directors in 2025.

**Subsequent Events**

On February 24, 2026, the Company's stockholders approved the Decoy Therapeutics Inc. 2026 Equity Incentive Plan (the "2026 Plan"), which replaces the 2015 Plan as the Company's primary equity compensation vehicle. Under the 2026 Plan, 91,667 shares of the Company's common stock have been authorized for issuance (as adjusted for the 1-for-12 reverse stock split effected on March 6, 2026). On April 2, 2026, the Company filed a Registration Statement on Form S-8 (File No. 333-294859) with the SEC registering the 91,667 shares issuable under the 2026 Plan, together with 13,615 shares issuable upon the exercise of options previously granted under the 2020 Plan and assumed by the Company in the Merger. Because the 2026 Plan was approved, and the Registration Statement on Form S-8 was filed, after December 31, 2025, the shares authorized under the 2026 Plan are not reflected in the table above.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT** 

The following table sets forth certain information regarding beneficial ownership of the Company's common stock as of April 30, 2026 by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•each person or group known by the Company to beneficially own more than 5% of the Company's outstanding common stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•each of the Company's directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•each of the Company's named executive officers; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•all of the Company's current executive officers and directors as a group.

The percentage ownership is based on 531,968 shares of common stock outstanding on May 22, 2026. The Company has determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of the Company's common stock issuable pursuant to the exercise of stock options or warrants or other securities (including out-of-the-money securities) that are either immediately exercisable or exercisable or vest within 60 days of such date. These shares are deemed to be outstanding and beneficially owned by the person holding those options, warrants, or securities for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.

Except as otherwise noted below, the address for each person or entity listed in the table is c/o Decoy Therapeutics Inc., 2450 Holcombe Blvd., Suite X, Houston, TX 77021. All share amounts have been adjusted to reflect the 1-for-15 reverse stock split effected on August 15, 2025 and the 1-for-12 reverse stock split effected on March 6, 2026.

---

| | | |
|:---|:---|:---|
|  | **Shares of**<br>**Common<br>Stock<br>Beneficially<br>Owned** | **Percent of**<br>**Common<br>Stock<br>Outstanding** |
| **Beneficial Owner** |  |  |
| Frederick E. Pierce(1) | 5112 | \* |
| Mark J. Rosenblum(2) | 1699 | \* |
| David J. Arthur(3) | 79 | \* |
| Barbara Hibner, Ph.D.(4) | 945 | \* |
| Peter Marschel(5) | 945 | \* |
| Tess Burleson(6) | 18 | \* |
| Arnold C. Hanish(7) | 18 | \* |
| Jonathan Lieber(8) | 18 | \* |
| Paul Lammers(9) | 17 | \* |
| William K McVicar(10) | 18 | \* |
| **All current executive officers and directors as a group (10 persons) (11)**  | 8869 | 1.7% |
| ***5% Stockholders:*** |  |  |
| CVI Investments, Inc. **(12)** | 59047 | 9.9% |

---

\* Represents beneficial ownership of less than 1%.

------

[**<u>**Table of Contents**</u>**](#toc_page)

(1)Includes (i) 1,389 shares of common stock and (ii) 945 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026. The 945 shares subject to options consist of (a) 422 shares underlying an option granted on April 1, 2022 at an exercise price of $59.28 per share, (b) 523 shares underlying an option granted on July 16, 2025 at an exercise price of $603.24 per share, in each case originally granted by Legacy Decoy and assumed by the Company in connection with the closing of the Merger. The options referenced in clause (b) are held of record by the Frederick E. Pierce II Living Trust dated January 28, 2011, of which Mr. Pierce is the trustee and sole beneficiary, and (iii) 1,389 Series A Warrants and 1,389 Series B Warrants.

(2)Includes (i) 1,681 shares of common stock held directly and (ii) 18 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026. The shares of common stock referenced in clause (i) are based on Mr. Rosenblum's direct ownership as reported on the Form 4 filed with the SEC on November 20, 2025 (reporting 20,177 shares directly held), as adjusted for the 1-for-12 reverse stock split effected on March 6, 2026. The 20,177 shares reported on the November 20, 2025 Form 4 included 20 shares of unvested restricted stock underlying a January 3, 2023 restricted stock unit award; additional monthly vesting has occurred under such award between November 20, 2025 and the record date.

(3)Includes (i) 34 shares of common stock and (ii) 45 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026. Mr. Arthur resigned as Chief Executive Officer on August 17, 2025 and continues to serve as a director. Pursuant to the Notice of Stock Option Amendment, dated February 20, 2024, the post-termination exercise period applicable to Mr. Arthur's options granted on September 10, 2019, March 23, 2020, July 14, 2020, December 2, 2020 and January 20, 2022 was extended from 90 days to 18 months upon the termination of his Continuous Service (as defined in the Salarius Pharmaceuticals 2015 Equity Incentive Plan) for any reason other than for Cause (as defined therein).

(4)Includes 945 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026. The 945 shares subject to options consist of (a) 422 shares underlying an option granted on April 1, 2022 at an exercise price of $59.28 per share and (b) 523 shares underlying an option granted on July 16, 2025 at an exercise price of $603.24 per share, in each case originally granted by Legacy Decoy and assumed by the Company in connection with the closing of the Merger.

(5)Includes 945 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026. The 931 shares subject to options consist of (a) 422 shares underlying an option granted on April 1, 2022 at an exercise price of $59.28 per share and (b) 523 shares underlying an option granted on July 16, 2025 at an exercise price of $603.24 per share, in each case originally granted by Legacy Decoy and assumed by the Company in connection with the closing of the Merger.

(6)Includes (i) 2 shares of common stock and (ii) 16 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026.

(7)Includes (i) 2 shares of common stock and (ii) 16 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026.

(8)Includes (i) 2 shares of common stock and (ii) 16 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026.

(9)Includes (i) 1 shares of common stock and (ii) 16 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026.

(10) Includes (i) 2 shares of common stock, (ii) 16 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026.

(11) Includes (i) 3,113 shares of common stock, (ii) 2,978 shares of common stock subject to options that are exercisable within 60 days of April 30, 2026, and (iii) 2,778 warrants to purchase shares of common stock that are held by the Company's executive officers and directors as a group.

(12) Based on a Schedule 13G/A filed by CVI Investments, Inc on February 20, 2026. The number of shares reported as beneficially owned consists of shares of common stock issuable upon the exercise of warrants. The address of the principal business office of CVI Investments, Inc. is P.O Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, KY1-1104, Cayman Islands. Heights Capital Management, Inc. is the investment manager of CVI Investments, Inc. and may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**CERTAIN RELATED-PERSON TRANSACTIONS**

The following includes a summary of transactions since January 1, 2024 to which the Company has been a party, in which the amount involved in the transaction exceeded the lesser of $120,000 or one percent of the average of the Company's total assets at year-end for the last two completed fiscal years, and in which any of the Company's directors, executive officers or, to the Company's knowledge, beneficial owners of more than 5% of the Company's capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change of control, and other arrangements, which are described under "Executive Compensation."

**The Merger**

On November 12, 2025, the Company (then known as Salarius Pharmaceuticals, Inc.) completed its previously announced merger with Legacy Decoy pursuant to the Merger Agreement. At the effective time of the Merger, each outstanding share of Legacy Decoy common stock was converted into the right to receive shares of the Company's common stock in accordance with an exchange ratio specified in the Merger Agreement, and each outstanding and unexercised option to purchase shares of Legacy Decoy common stock was assumed by the Company and converted into an option to purchase shares of the Company's common stock in accordance with the exchange ratio specified in the Merger Agreement.

Each of Mr. Pierce, Dr. Hibner and Mr. Marschel, each a co-founder, executive officer and/or director of Legacy Decoy prior to the closing of the Merger, received shares of the Company's Preferred Stock and each hold options to purchase shares of the Company's common stock assumed by the Company in the Merger.

**Other Related Person Transactions**

As of December 31, 2025, one officer/founder of the Company had an outstanding Demand Note in the principal amount of $55,555, plus accrued interest of approximately $13,000. This note accrues interest at 10% and has a maturity date of December 28, 2024. An agreement to exchange this note for the Company's Series B Preferred Stock, contingent upon Closing of the Merger, has been executed.

As of December 31, 2025, one family member of an officer/founder of the Company had an outstanding Demand Note in the amount of $83,333, plus accrued interest of approximately $22,000 and an outstanding Promissory Note in the amount of $100,000, plus accrued interest of approximately $20,000. An agreement to exchange this note for the Company's Series B Preferred Stock, contingent upon Closing of the Merger, has been executed. During the second half of 2024 and first half of 2025, founders of the Legacy Decoy loaned Legacy Decoy approximately $140,000 through non-interest bearing, open-ended maturity notes. As of July 22, 2025 these notes were amended to have a maturity date in November 2026.

**Indemnification Agreements**

The Company has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in its Certificate of Incorporation and Bylaws. These agreements, among other things, require the Company to indemnify its directors and executive officers for certain expenses, including attorneys' fees, judgments, fines, and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of the Company's directors or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at the Company's request. The Company believes that these charter provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.

The limitation of liability and indemnification provisions in the Company's Certificate of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit the Company and its stockholders. A stockholder's investment may decline in value to the extent the

------

[**<u>**Table of Contents**</u>**](#toc_page)

Company pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

**Policies and Procedures for Transactions with Related Persons**

The Company has adopted a written Related Person Transactions Policy that sets forth its policies and procedures regarding the identification, review, consideration, and oversight of "related person transactions." For purposes of this policy only, a "related person transaction" is a transaction, arrangement, or relationship (or any series of similar transactions, arrangements or relationships) in which the Company or any of its subsidiaries are participants involving an amount that exceeds $120,000, in which any "related person" has a material interest.

Transactions involving compensation for services provided to the Company as an employee, consultant, or director are not considered related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of the Company's voting securities (including its common stock), including any of their immediate family members and affiliates, including entities owned or controlled by such persons.

Under the policy, the related person in question or, in the case of transactions with a holder of more than 5% of any class of the Company's voting securities, an officer with knowledge of the proposed transaction, must present information regarding the proposed related person transaction to the Company's Audit Committee (or, where review by the Audit Committee would be inappropriate, to another independent body of the Board of Directors) for review. To identify related person transactions in advance, the Company relies on information supplied by its executive officers, directors, and certain significant stockholders. In considering related person transactions, the Company's Audit Committee considers the relevant available facts and circumstances, which may include, but is not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the risks, costs, and benefits to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on a director's independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the terms of the transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the availability of other sources for comparable services or products; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the terms available to or from, as the case may be, unrelated third parties.

The Company's Audit Committee will approve only those transactions that it determines are fair to the Company and in its best interests.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**AUDIT COMMITTEE REPORT**

*The following report of the Audit Committee does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any other filing by the Company under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.*

The Audit Committee is a committee of the Board of Director comprised solely of independent directors as required by the listing standards of Nasdaq and rules and regulations of the SEC. The Audit Committee provides assistance to the Board of Director in fulfilling its legal and fiduciary obligations in matters involving the Company's accounting, auditing, financial reporting, internal control and legal compliance functions by approving the services performed by the Company's independent registered public accountants and reviewing their reports regarding the Company's accounting practices and systems of internal accounting controls as set forth in a written charter adopted by the Board of Director, which is available on the Company's website at http://www.decoytx.com. The composition and responsibilities of the Audit Committee, as reflected in its charter, are intended to be in accordance with applicable requirements. The Audit Committee reviews and assesses the adequacy of its charter and the Audit Committee's performance on an annual basis.

The Company's management is responsible for preparing the Company's financial statements and the independent registered public accountants are responsible for auditing those financial statements. The Audit Committee is responsible for overseeing the conduct of these activities by the Company's management and the independent registered public accountants. In this context, the Audit Committee has met and held discussions with management and the independent registered public accountants. Management represented to the Audit Committee that the Company's consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, and the Audit Committee has reviewed and discussed the consolidated financial statements with management and the independent registered public accountants.

The Audit Committee has discussed with the independent registered public accountants matters required to be discussed by Auditing Standard No. 1301, as adopted by the PCAOB and approved by the SEC. In addition, the independent registered public accountants provided to the Audit Committee the written disclosures and letter from the independent registered public accountants as required by applicable requirements of the PCAOB regarding the independent registered public accountants' communications with the Audit Committee concerning independence and has discussed such accountants' independence from the Company and its management.

The Audit Committee has discussed with management the procedures for selection of consultants and fully considered whether those services provided by the independent registered public accountants are compatible with maintaining such accountants' independence. The Audit Committee has discussed with the Company's management and its independent registered public accountants, with and without management present, their evaluations of the Company's internal accounting controls and the overall quality of the Company's financial reporting.

In reliance on the reviews and discussions with management and the independent registered public accountants referred to above, the Audit Committee recommended to the Board of Directors, and the Board of Directors has approved, the inclusion of the audited financial statements in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as amended, for filing with the SEC.

------

[**<u>**Table of Contents**</u>**](#toc_page)

In addition, the Audit Committee has selected Ernst & Young LLP as our independent registered public accounting firm to audit our books, records and accounts and our subsidiaries for the fiscal year ending December 31, 2026.

---

| |
|:---|
| Respectfully submitted, |
| Mr. Arnold C. Hanish, Chair |
| Ms. Tess Burleson |
| Mr. Jonathan Lieber |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PROPOSAL 1** 

**ELECTION OF DIRECTORS**

**Directors and Nominees**

Our Board of Directors consists of seven (7) directors which are divided into three classes: Class I, Class II, and Class III. Each class has a three-year term.

Our Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee, has nominated Patricia Gauthier, Jonathan Lieber, and Frederick J. Pierce as nominees for election as Class II directors at the Annual Meeting. If elected at the Annual Meeting, these directors would serve until the annual meeting of stockholders to be held in 2029 or until their respective successors are duly elected and qualified or until such individual's earlier resignation, removal, death or incapacity. If any nominee is unable or declines to serve as director at the time of the Annual Meeting, proxies will be voted for any nominee designated by our Board of Directors to fill the vacancy.

Biographical information and the attributes, skills and experience of each nominee that led our Nominating and Corporate Governance Committee and Board of Directors to determine that such nominee should serve as a director are discussed in the "Directors and Executive Officers" section of this proxy statement and is incorporated into this section by reference.

**Required Vote**

Directors are elected by the affirmative vote of the holders of a majority of the voting power of the capital stock entitled to vote and present in person or represented by proxy at the Annual Meeting. An abstention has the same effect as a vote "**AGAINST**" a director nominee in Proposal 1. Broker non-votes will have no effect. Further, if the majority of the votes cast for a director are marked "AGAINST" or "ABSTAIN" then notwithstanding the valid election of such director, the Bylaws stipulate that such director will voluntarily tender his or her irrevocable resignation for consideration by our Nominating and Corporate Governance Committee. Our Board of Directors will determine whether to accept the resignation of such director, taking into account the recommendation of the Nominating and Corporate Governance Committee.

**OUR BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ELECTION OF PATRICIA GAUTHIER, JONATHAN LIEBER, AND FREDERICK E. PIERCE AS CLASS II DIRECTORS OF THE COMPANY**

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PROPOSAL 2**

**NON-BINDING ADVISORY VOTE ON EXECUTIVE COMPENSATION**

As required under Section 14A of the Exchange Act, the Board of Directors is submitting a "say on pay" proposal to our stockholders with the opportunity to vote to approve, on a nonbinding, advisory basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the compensation disclosure rules of the SEC.

Our executive compensation programs are designed to reward our named executive officers for the achievement of short-term and long-term strategic and operational goals, while at the same time avoiding the encouragement of unnecessary or excessive risk taking. Stockholders are encouraged to read the Executive Compensation section of this proxy statement for a more detailed discussion of how our compensation programs reflect our objectives.

We are asking our stockholders to indicate their support for our named executive officer compensation as described in this proxy statement. This proposal, commonly known as a "say-on-pay" proposal, gives our stockholders the opportunity to express their views on our named executive officers' compensation. This vote is advisory, which means that the vote on executive compensation is not binding on us, our Board of Directors or the Compensation Committee. This vote is not intended to address any specific item of compensation, but rather the vote relates to the compensation of our named executive officers as a whole, as described in this proxy statement in accordance with the compensation disclosure rules of the SEC. Accordingly, we will ask our stockholders to vote for the following resolution at the Annual Meeting:

"**RESOLVED**, that the Company's stockholders approve, on a non-binding advisory basis, the compensation of the named executive officers, as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the SEC, including the Summary Compensation Table and the other related tables and disclosure."

**Required Vote**

Approval of the compensation of our named executive officers on a non-binding advisory basis requires the affirmative vote of a majority of the voting power of the capital stock entitled to vote and present in person or represented by proxy at the Annual Meeting. An abstention has the same effect as a vote "**AGAINST**" Proposal 2. Broker non-votes will have no effect.

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.**

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PROPOSAL 3** 

**RATIFICATION OF THE SELECTION OF INDEPENDENT REGISTERED PUBLIC** 

**ACCOUNTING FIRM**

Our Audit Committee, which is composed entirely of non-employee independent directors, has selected Ernst & Young LLP as independent accountants to audit our books, records, and accounts and our subsidiaries for the fiscal year ending December 31, 2026. Our Board of Directors has endorsed this appointment. Ratification of the selection of Ernst & Young LLP by stockholders is not required by law. However, as a matter of good corporate practice, such selection is being submitted to the stockholders for ratification at the Annual Meeting. If the stockholders do not ratify the selection, our Board of Directors and the Audit Committee will reconsider whether or not to retain Ernst & Young LLP, but may retain Ernst & Young LLP. Even if the selection is ratified, the Audit Committee in its discretion may change the appointment at any time during the year if it determines that such change would be in our best interests the best interests of our stockholders. Representatives of Ernst & Young LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement, if they desire to do so, and will be available to respond to appropriate questions.

**Principal Accountant Fees and Services**

***Current Independent Registered Public Accounting Firm Fees***

The following table sets forth the total fees paid to EY and its affiliates with respect to the years ended December 31, 2024 and December 31, 2025.

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2024** | **2025** |
| Audit fees(1) | $255038 | $908179 |
| Audit-related fees(2) |  |  |
| Tax fees(3) |  |  |
| All other fees(4) | 85000 |  |
| **Total** | $**340038** | $**908179** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Consists of fees billed for professional services rendered for the audit of the Company's annual financial statements and services provided in connection with the Company's registration statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Represents the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit or review of the Company's consolidated financial statements that are not reported under "Audit Fees."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Consists of fees billed for tax compliance, tax advice, tax planning and tax return preparation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Consists of fees billed for services, other than those described above under Audit fees and Tax fees.

**Audit Committee Pre-Approval Policies and Procedures**

The Company's Audit Committee has implemented pre-approval policies and procedures related to the provision of audit and non-audit services. Under these procedures, the Audit Committee pre-approves both the type of services to be provided by Ernst & Young LLP and the estimated fees related to these services.

During the approval process, the Audit Committee considers the impact of the types of services and the related fees on the independence of the registered public accountant. The services and fees must be deemed compatible with the maintenance of such accountants' independence, including compliance with SEC rules and regulations.

------

[**<u>**Table of Contents**</u>**](#toc_page)

Throughout the year, the Audit Committee reviews for any revisions to the estimates of audit and non-audit fees initially approved. The Audit Committee reviewed and pre-approved all audit services and permitted non-audit services performed during the years ended December 31, 2025 and December 31, 2024.

**Required Vote**

Ratification of the appointment of Ernst & Young LLP requires the affirmative vote of a majority of the voting power of the capital stock entitled to vote and present in person or represented by proxy at the Annual Meeting. An abstention has the same effect as a vote "**AGAINST**" Proposal 3. Broker non-votes will have no effect. If your shares are held in street name, your broker, bank or other nominee has discretionary authority to vote shares held through it in the absence of your instruction regarding how your shares should be voted. Unless marked to the contrary, proxies received will be voted "FOR" ratification of the appointment.

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE RATIFICATION OF**

**ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.**

------

[**<u>**Table of Contents**</u>**](#toc_page)

**OTHER MATTERS**

The Board of Directors does not know of any other business that will be presented at the Annual Meeting. If any other business is properly brought before the Annual Meeting, the proxy holders will vote in accordance with their judgment unless you direct them otherwise. Whether or not you intend to attend the Annual Meeting, we urge you to vote by telephone or the Internet.

**Availability of Annual Report on Form 10-K**

A copy of an Annual Report on Form 10-K, as amended, including the financial statements and schedules thereto, required to be filed with the SEC for our most recent fiscal year, may be found on our website, investors.decoytx.com. In addition, we will provide each beneficial owner of our securities with a copy of the Annual Report without charge, upon receipt of a written request from such person. Such request should be sent to the office of our Corporate Secretary, Decoy Therapeutics Inc., 2450 Holcombe Blvd., Suite X, Houston, TX 77021.

**Householding of Proxy Materials**

To reduce the expense of delivering duplicate proxy materials to stockholders who may have more than one account holding our stock but who share the same address, we have adopted a procedure approved by the SEC called "householding." Under this procedure, certain stockholders of record who have the same address and last name will receive only one copy of our proxy materials until such time as one or more of these stockholders notifies us that they want to receive separate copies. This procedure reduces duplicate mailings and saves printing costs and postage fees, as well as natural resources. Stockholders who participate in householding will continue to have access to and utilize separate proxy voting instructions.

If you receive a single set of proxy materials as a result of householding and you would like to have separate copies of proxy materials mailed to you, please submit a request to our Secretary at 2450 Holcombe Blvd., Suite X, Houston, TX 77021 and we will promptly send you what you have requested. You can also contact our Secretary at the above address if you received multiple copies of the annual meeting materials and would prefer to receive a single copy in the future, or if you would like to opt out of householding for future mailings.

**Stockholder Proposals for the 2027 Annual Meeting**

To be considered for inclusion in next year's proxy materials, your proposal must be submitted in writing by February 4, 2027, to our Secretary at 2450 Holcombe Blvd., Suite X, Houston, TX 77021. If you wish to submit any other motion related to business proposed to be brought before next year's annual meeting of stockholders, you must provide the specified information required by our Bylaws to our Secretary at 2450 Holcombe Blvd., X, Houston, TX 77021 not more than 120 days (February 4, 2027) nor less than 90 days (March 8, 2027) prior to the first anniversary of the date the proxy statement was provided to our stockholders in connection with the 2026 Annual Meeting of stockholders; however, if the annual meeting is called for a date that is more than 30 days before or after the anniversary date of the 2026 annual meeting of stockholders, notice by the stockholder must be received by our Secretary not later than the close of business on the later of (i) the 90<sup>th</sup>day prior to the 2027 annual meeting of stockholders and (ii) the 10<sup>th</sup>day following the day on which public announcement of the date of the 2027 annual meeting of stockholders is publicly given. You are also advised to review our Bylaws, which contain additional requirements regarding advance notice of stockholder proposals and director nominations.

------

[**<u>**Table of Contents**</u>**](#toc_page)

In addition to satisfying the foregoing advance notice requirements under our Bylaws, to comply with the universal proxy rules under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must provide written notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than May 17, 2027, which is 60 days prior to the one-year anniversary of the Annual Meeting.

**Other Business**

Our Board of Directors does not know of any other business that will be presented at the Annual Meeting. If any other business is properly brought before the Annual Meeting, the proxy holders will vote in accordance with their judgment unless you direct them otherwise. Whether or not you intend to attend the Annual Meeting, we urge you to vote by Internet or telephone.

---

| | | |
|:---|:---|:---|
|  | By Order of the Board of Directors, | By Order of the Board of Directors, |
| Houston, TX |  |  |
| June 4, 2026 |  | /s/ Frederick E. Pierce |
|  |  | Frederick E. Pierce |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

![img45420450_2.jpg](img45420450_2.jpg)

------

[**<u>**Table of Contents**</u>**](#toc_page)

![img45420450_3.jpg](img45420450_3.jpg)

------